var title_f10_63_11248="Group B streptococcus and pregnancy";
var content_f10_63_11248=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Group B streptococcus and pregnancy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/63/11248/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11248/contributors\" id=\"au4228\">",
"       Karen M Puopolo, MD, PhD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11248/contributors\" id=\"au4378\">",
"       Carol J Baker, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/63/11248/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11248/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11248/contributors\" id=\"se2060\">",
"       Daniel J Sexton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/63/11248/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11248/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/63/11248?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Group B streptococcus (GBS) is a bacterium that can cause serious infections in pregnant women and newborn babies. GBS is one of many types of streptococcal bacteria, sometimes called \"strep.\"",
"    </p>",
"    <p>",
"     This article discusses GBS, its effect on pregnant women and infants, and ways to prevent complications of GBS. More detailed information about GBS is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=see_link\">",
"      \"Group B streptococcal infection in pregnant women\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS GROUP B STREP INFECTION?",
"     </span>",
"    </p>",
"    <p>",
"     GBS is commonly found in the digestive system and the vagina. In healthy adults, GBS is not harmful and does not cause problems. But in pregnant women and newborn infants, being infected with GBS can cause serious illness.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Approximately one in three to four pregnant women in the US carries GBS in their gastrointestinal system",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       in their vagina. Carrying GBS is not the same as being infected. Carriers are not sick and do not need treatment during pregnancy. There is no treatment that can stop you from carrying GBS.",
"      </li>",
"      <li>",
"       Pregnant women who are carriers of GBS infrequently become infected with GBS. GBS can cause urinary tract infections, infection of the amniotic fluid (bag of water), and infection of the uterus after delivery. GBS infections during pregnancy may lead to preterm labor.",
"      </li>",
"      <li>",
"       Pregnant women who carry GBS can pass on the bacteria to their newborns, and some of those babies become infected with GBS. Newborns who are infected with GBS can develop pneumonia (lung infection), septicemia (blood infection), or meningitis (infection of the lining of the brain and spinal cord).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These complications can be prevented by giving intravenous (IV) antibiotics during labor to any woman who is at risk of GBS infection. You are at risk of GBS infection if:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       You have a urine culture during your current pregnancy showing GBS",
"      </li>",
"      <li>",
"       You have a vaginal",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       rectal culture during your current pregnancy showing GBS",
"      </li>",
"      <li>",
"       You had an infant infected with GBS in the past",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      GROUP B STREP PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Most doctors and nurses recommend a urine culture early in your pregnancy to be sure that you do not have a bladder infection. If you urine culture shows GBS or other bacteria, you may be treated with an antibiotic.",
"    </p>",
"    <p>",
"     Expert groups recommend that",
"     <strong>",
"      all",
"     </strong>",
"     pregnant women have a GBS culture at 35 to 37 weeks of pregnancy. The culture is done by swabbing the vagina and rectum. If your GBS culture is positive, you will be given an IV antibiotic during labor.",
"    </p>",
"    <p>",
"     If you have positive GBS culture and you have an allergy to penicillin, be sure your doctor and nurse are aware of this allergy. You may need an additional test to determine which antibiotic should be used during labor.",
"    </p>",
"    <p>",
"     Being treated with an antibiotic during labor greatly reduces the chance that you or your newborn will develop infections related to GBS.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15858777\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15858785\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193258\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H866563476\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=see_link\">",
"      Group B streptococcal infection in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36936?source=see_link\">",
"      Group B streptococcal infections in nonpregnant adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9621?source=see_link\">",
"      Group B streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40984?source=see_link\">",
"      Vaccines for the prevention of group B streptococcal disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/001366.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/001366.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Center for Disease Control and Prevention (available in Spanish)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/GroupBstrep/general/gen_public_faq.htm\">",
"      www.cdc.gov/GroupBstrep/general/gen_public_faq.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?10/63/11248/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/63/11248?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11248/abstract/1\">",
"      Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11248/abstract/2\">",
"      Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002; 347:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11248/abstract/3\">",
"      Eschenbach DA. Prevention of neonatal group B streptococcal infection. N Engl J Med 2002; 347:280.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_63_11248=[""].join("\n");
var outline_f10_63_11248=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS GROUP B STREP INFECTION?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           GROUP B STREP PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11249="Sept asthma epidemic";
var content_f10_63_11249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    The number of asthma hospitalizations by age group (in multiples of the mean) in Canada graphed by the week of the year",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Johnston, NW, Johnston, SL, Norman, GR, et al. The September epidemic of asthma hospitalization: School children as disease vectors. J Allergy Clin Immunol 2006; 117:557. Copyright &copy; 2006. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11249=[""].join("\n");
var outline_f10_63_11249=null;
var title_f10_63_11250="Trap door effect";
var content_f10_63_11250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trap door effect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 611px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Round or elliptical lacerations with partial avulsions (figure A) are prone to bulging in the flap during healing (figure B). This effect can be minimized by approximation of the subcutaneous tissue to the base of the flap and careful apposition of the skin layers. Alternatively, small lacerations may be revised by removal of the flap and pedicle (figure C). Large lacerations warrant primary closure and referral to a plastic surgeon for elective Z-plasty.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11250=[""].join("\n");
var outline_f10_63_11250=null;
var title_f10_63_11251="Sodium thiosulfate: Patient drug information";
var content_f10_63_11251=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium thiosulfate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     see \"Sodium thiosulfate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/56/1924?source=see_link\">",
"     see \"Sodium thiosulfate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cyanide poisoning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop skin problems from some drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702948",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium thiosulfate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12124 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11251=[""].join("\n");
var outline_f10_63_11251=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013219\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013218\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013223\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013224\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013226\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013221\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013228\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=related_link\">",
"      Sodium thiosulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/56/1924?source=related_link\">",
"      Sodium thiosulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11252="Ovarian cancer diagnosis and staging";
var content_f10_63_11252=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/63/11252/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11252/contributors\" id=\"au4486\">",
"       Lee-may Chen, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11252/contributors\" id=\"au4266\">",
"       Jonathan S Berek, MD, MMS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/63/11252/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11252/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/63/11252/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11252/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/63/11252?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Ovarian cancer is the second most common cancer of the reproductive organs among women in the United States [",
"     <a class=\"abstract\" href=\"UTD.htm?10/63/11252/abstract/1\">",
"      1",
"     </a>",
"     ]. The average age at diagnosis of ovarian cancer is 63 years old [",
"     <a class=\"abstract\" href=\"UTD.htm?10/63/11252/abstract/2\">",
"      2",
"     </a>",
"     ]. The lifetime risk of developing ovarian cancer is approximately 1.4 percent.",
"     <br/>",
"    </p>",
"    <p>",
"     There are several different types of cancer that can develop in the ovary; epithelial ovarian cancer (EOC) is the most common type and is the subject of this topic review. We will hereafter use the term ovarian cancer to refer to EOC.",
"    </p>",
"    <p>",
"     This topic review discusses the diagnosis and staging of ovarian cancer. A separate topic review is available that discusses ovarian cancer treatment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     The following factors increase the risk of developing ovarian cancer:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Being a white person",
"      </li>",
"      <li>",
"       Never being pregnant",
"      </li>",
"      <li>",
"       Early age of menarche (the onset of the menstrual periods) or late age of menopause",
"      </li>",
"      <li>",
"       Family history of ovarian, breast, or endometrial (uterine) cancer, particularly if the person inherits a specific type of genetic abnormality called a",
"       <em>",
"        BRCA1",
"       </em>",
"       or",
"       <em>",
"        BRCA2",
"       </em>",
"       mutation. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"        \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Family history of Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]). Women in families with this trait have up to a 60 percent chance of endometrial cancer and a 10 to 12 percent chance of ovarian cancer [",
"       <a class=\"abstract\" href=\"UTD.htm?10/63/11252/abstract/3\">",
"        3",
"       </a>",
"       ].",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     During the early stages of ovarian cancer, symptoms are often vague and ill-defined. Symptoms may include pelvic or abdominal discomfort, bloating, difficulty eating or feeling full, increased abdominal size, or urinary symptoms (urgency and frequency).",
"    </p>",
"    <p>",
"     In some women, ovarian cancer is initially suspected when a mass or lump is felt during a routine pelvic examination. However, a mass is not always detectable in the early stages of ovarian cancer. Even when a mass is detected, it does not necessarily mean that the woman has ovarian cancer. A number of other non-cancerous conditions can cause masses.",
"    </p>",
"    <p>",
"     Because the initial symptoms are vague and nonspecific, the majority of women have advanced-stage disease by the time the diagnosis is made. At this point, the woman may have more prominent symptoms such as abdominal distention (swelling), nausea, or a significant loss of appetite.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If ovarian cancer is suspected because of symptoms",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     an abnormal physical examination, imaging tests of the abdomen and pelvis (such as a CT scan or MRI scan) are usually recommended initially. Radiology tests such as these do not provide enough information by themselves to definitively diagnose ovarian cancer, although they may provide important information about the location",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     extent of a possible cancer.",
"    </p>",
"    <p>",
"     The only way to diagnose ovarian cancer with certainty is with an exploratory operation. If a growth that appears cancerous is seen on the ovary, the entire ovary is usually removed. Biopsy of an ovary with suspected ovarian cancer is usually not performed, since a biopsy may spread cancer cells and result in a more advanced cancer. In premenopausal women, removal of a single ovary will not result in menopause or infertility if the other ovary is healthy (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Exploratory laparotomy'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Laparoscopy (a procedure to explore the abdomen through a small incision using a laparoscope) may be used to evaluate a pelvic mass. Open surgery is usually preferred when there is high suspicion of malignancy. In rare cases where open exploratory surgery is not possible because the woman is in poor health or the disease is far advanced, a diagnostic laparoscopy may also be recommended. In other cases, a nonsurgical procedure that removes fluid from the abdomen or chest with a needle (called paracentesis or thoracentesis) is done to confirm the diagnosis before chemotherapy begins.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Tumor markers (CA 125)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prior to or immediately following surgery, most women who are suspected of having or are diagnosed with ovarian cancer undergo a blood test to measure the level of a protein tumor marker called CA 125. This marker is normally less than 35",
"     <span class=\"nowrap\">",
"      U/mL.",
"     </span>",
"     CA 125 levels are elevated (above 65",
"     <span class=\"nowrap\">",
"      U/mL)",
"     </span>",
"     in 80 percent of women with advanced ovarian cancer (see below).",
"    </p>",
"    <p>",
"     An elevated CA 125 is not diagnostic of ovarian cancer. It is often negative in women who have ovarian cancer. Also, it can often be positive for reasons other than ovarian cancer (eg, endometriosis, fibroids). It is important to measure it before surgery so that it can be used as a baseline value to monitor the success of treatment if ovarian cancer is found.",
"    </p>",
"    <p>",
"     The use of CA 125 as a screening test for ovarian cancer is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"      \"Patient information: Ovarian cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Initial surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;A procedure called exploratory laparotomy is typically recommended for women who are suspected of having ovarian cancer. This surgery is most successful in accurately diagnosing and treating ovarian cancer when it is performed by a gynecologic oncologist, a physician who has had extensive training in the management of cancers of the female reproductive system.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Exploratory laparotomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;During the procedure, usually, a vertical (up and down) abdominal incision is made and the surgeon examines the organs within the pelvis and abdomen for signs of cancer. Samples of tissue and fluid are taken from the following areas:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Within the abdominal cavity (also called the peritoneal cavity)",
"      </li>",
"      <li>",
"       The ovary",
"      </li>",
"      <li>",
"       Neighboring lymph nodes",
"      </li>",
"      <li>",
"       Other abdominal organs",
"      </li>",
"      <li>",
"       The omentum (the apron of fat that covers and connects the organs of the abdomen and pelvis)",
"      </li>",
"      <li>",
"       The surface of the diaphragm",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     While still in the operating room, the surgeon sends the tissues for microscopic examination by a pathologist, a physician who has specialized training in the examination of tissues. The pathologist examines the tissue samples during the surgery (called frozen section analysis), and then immediately notifies the surgeon as to whether definite signs of cancer are present. A more thorough examination of the fluid and tissue samples is performed after the surgery is completed to ensure that the initial diagnosis was correct.",
"    </p>",
"    <p>",
"     If the pathologist finds evidence of ovarian cancer on frozen section analysis, the surgeon will then attempt to remove as much of the cancerous tissue as possible. This procedure is termed surgical staging and is an important first step in the treatment of ovarian cancer.",
"    </p>",
"    <p>",
"     In most cases, the uterus, both fallopian tubes, and both ovaries are also removed (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). If the cancer has spread to other organs, those organs, or affected portions of them, may be removed as well. As much tumor as possible is removed. This is called \"debulking\" or cytoreduction. Treatment outcomes are best in women whose surgery removes all visible tumor (termed optimal debulking). Having the surgical procedure performed by a gynecologic oncologist provides the best chance for optimal debulking.",
"    </p>",
"    <p>",
"     However, in some cases, if a young woman wished to preserve her ability to bear children in the future, it may be possible to leave the uterus, one fallopian tube, and one ovary in place. This would only be possible if these structures seem to be unaffected by the cancer. The surgeon and patient should discuss this option before the operation is undertaken.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Minimally invasive procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some patients, a less invasive procedure called exploratory laparoscopy may be performed. In this procedure, a flexible tube (a laparoscope) is inserted through a small incision in the abdomen. The laparoscope has a camera that the surgeon uses to visualize the contents of the abdomen and pelvis. This less invasive approach may be chosen for a young woman with a mass that is unlikely to be an ovarian cancer.",
"    </p>",
"    <p>",
"     However, an open laparotomy is generally preferred because it allows the surgeon to more easily and completely visualize the abdominal contents and remove any suspicious masses.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      STAGING",
"     </span>",
"    </p>",
"    <p>",
"     Based upon the findings during exploratory surgery, the tumor is formally \"staged\" according to the size, extent, and location of the cancer. Accurate staging during surgery is very important in determining a woman's long-term outcome (prognosis) and choosing the appropriate treatment regimen after surgery.",
"    </p>",
"    <p>",
"     The stage of an ovarian cancer is defined by a Roman numeral designation between I and IV, and subdivided by the letters A, B, and C. In general, the stages I, II, III, and IV refer to the location of tumor involvement, while the subdivisions A, B, and C define the extent of tumor involvement. A higher stage of disease indicates more extensive tumor involvement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Early stage cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stage I and II disease are considered early stage ovarian cancer:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In stage IA and IB disease, the cancer is limited to one or both or ovaries, and the capsule or membrane covering the ovaries has not been broken by the cancer's growth.",
"      </li>",
"      <li>",
"       In stage IC disease, the capsule of either ovary may have ruptured or there may be signs suggesting that cancer cells have begun to spread within the pelvis (ie, there are cancerous cells in the fluid taken from the peritoneal cavity during surgery).",
"      </li>",
"      <li>",
"       In stage II disease, other pelvic organs, such as the uterus or fallopian tubes, are involved with the tumor, and there may be early signs that the cancer has spread beyond the pelvis.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Advanced stage disease",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In stage III disease, the cancer is confined to the abdomen and the abdominal lymph nodes.",
"      </li>",
"      <li>",
"       In stage IV disease, the cancer has spread to distant sites such as the liver or lungs.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Recommendations for treatment after surgery depend upon the disease stage. While a course of chemotherapy is recommended after surgery for all women with stage III or IV ovarian cancer, it may or may not be recommended for women who have stage I or II disease. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     A number of factors influence the success of treatment for ovarian cancer. Treatment tends to be more successful when the cancer is diagnosed at an early stage and in younger women (below the age of 67). One of the most important factors influencing the outcome of treatment is the amount of tumor that remains after the initial surgery (ie, the success of the initial debulking procedure). This is the reason that the surgeon aims to remove as much of the cancerous tissue as possible during the initial surgery. As noted above, this is most likely when the surgeon performing the debulking procedure is a gynecologic oncology specialist.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Complete response",
"     </span>",
"     &nbsp;&mdash;&nbsp;At the end of treatment (both surgery and chemotherapy), a patient is considered to have a \"complete response\" if the physical examination is normal, there is no evidence of cancer on imaging studies (such as a CT scan), and the blood levels of CA 125 are normal. However, even when all of these criteria are met, small, sometimes microscopic amounts of residual cancer (ie, not visible on imaging studies) can still be present.",
"    </p>",
"    <p>",
"     In some women, a second surgical exploration (termed a second-look laparotomy or laparoscopy) may be performed to more conclusively evaluate the response to treatment. However, it is unclear whether the findings at second-look surgery influence later treatment and prognosis. For this reason, the benefit of second look surgery is controversial, and it is not routinely recommended for all women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Recurrence",
"     </span>",
"     &nbsp;&mdash;&nbsp;Even women who have a complete response to initial therapy (as determined by physical examination, imaging studies,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     second look surgery) can have a recurrence of ovarian cancer at a later time. The likelihood of a tumor recurrence is highest in women with more advanced stage disease at diagnosis, particularly if the initial debulking surgery was unable to remove all visible tumor.",
"    </p>",
"    <p>",
"     Signs of recurrent ovarian cancer include new symptoms (eg, abdominal bloating, back pain), a rising blood level of CA 125, or new findings on a follow-up CT scan. Further treatment may not be recommended immediately if the CA 125 level is slowly rising, there are no new symptoms, and a CT scan shows no new abnormalities that could indicate a disease recurrence.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of ovarian cancer is discussed at length in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"        www.cancer.gov/clinicaltrials/learning/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413447837\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11168982\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=see_link\">",
"      Patient information: Ovarian cancer screening (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11168999\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25847?source=see_link\">",
"      Epithelial ovarian cancer: Second look surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=see_link\">",
"      Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/537?source=see_link\">",
"      Intraperitoneal chemotherapy for treatment of ovarian cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=see_link\">",
"      Management of ovarian cancer in pregnant women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link\">",
"      Ovarian tumors of low malignant potential",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"      Screening for ovarian cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28070?source=see_link\">",
"      Surgery for recurrent epithelial ovarian cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People Living With Cancer: The official patient information website of the American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Women's Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.wcn.org/\">",
"      www.wcn.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gynecologic Oncology Group",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gog.org/gynecologiccancerinformation.html\">",
"      www.gog.org/gynecologiccancerinformation.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Ovarian Cancer Coalition",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ovarian.org/\">",
"      www.ovarian.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/63/11252?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11252/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/ovary.html (Accessed on May 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11252/abstract/3\">",
"      Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354:261.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_63_11252=[""].join("\n");
var outline_f10_63_11252=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11253="Technique of Syme amputation";
var content_f10_63_11253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=47\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=47\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Technique of Syme amputation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 683px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11253=[""].join("\n");
var outline_f10_63_11253=null;
var title_f10_63_11254="Evaluation and treatment of hypomagnesemia";
var content_f10_63_11254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and treatment of hypomagnesemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/63/11254/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11254/contributors\">",
"     Alan S L Yu, MB, BChir",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11254/contributors\">",
"     Gunjeet K Kala Ahluwalia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/63/11254/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11254/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/63/11254/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11254/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/63/11254/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the body&rsquo;s magnesium stores are intracellular, principally within bone. In the extracellular fluid, magnesium can be ionized (free), bound to anions, or bound to protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The plasma magnesium concentration is not usually measured as part of routine blood tests. Thus, the identification of patients with hypomagnesemia often requires clinical suspicion in patients with risk factors for hypomagnesemia (eg, chronic diarrhea, proton pump inhibitor therapy, alcoholism, diuretic use) or with clinical manifestations of hypomagnesemia (eg, unexplained hypocalcemia, refractory hypokalemia, neuromuscular disturbances, ventricular arrhythmias) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the evaluation and treatment of hypomagnesemia. The regulation of magnesium balance, and the causes and clinical manifestations of hypomagnesemia are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients diagnosed with hypomagnesemia, the cause can usually be obtained from the history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no etiology is apparent, the distinction between gastrointestinal and renal losses can be made by measuring the 24-hour urinary magnesium excretion or the fractional excretion of magnesium on a random urine specimen.",
"   </p>",
"   <p>",
"    The latter can be calculated from the following formula (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?7/50/7970?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?17/59/18354?source=see_link\">",
"     calculator 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;UMg &nbsp;x &nbsp;PCr",
"    <br/>",
"    &nbsp;FEMg &nbsp; &nbsp;= &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; &nbsp;x &nbsp; &nbsp;100 percent",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (0.7 &nbsp;x &nbsp;PMg) &nbsp;x &nbsp;UCr",
"   </p>",
"   <p>",
"    The terms U and P refer to the urine and plasma concentrations of magnesium (Mg) and creatinine (Cr). The plasma magnesium concentration is multiplied by 0.7, since only about 70 percent of the circulating magnesium is free (not bound to albumin) and therefore able to be filtered across the glomerulus.",
"   </p>",
"   <p>",
"    Renal magnesium excretion should be reduced in patients with plasma magnesium depletion. Thus, measurement of 24-hour urinary magnesium excretion or the fractional excretion of magnesemia can help distinguish between gastrointestinal and renal losses of magnesium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A daily excretion of more than 10 to 30 mg (in a 24-hour urine specimen) or a fractional excretion of magnesium above 2 percent in a person with hypomagnesemia and normal renal function indicates renal magnesium wasting.",
"     </li>",
"     <li>",
"      In contrast, a 24-hour urinary magnesium excretion less than 10 mg or a fractional excretion of magnesium less than 2 percent usually indicates an extrarenal source of magnesium losses (typically gastrointestinal).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study of 74 hypomagnesemic patients, for example, the mean fractional excretion of magnesium in patients with hypomagnesemia of extrarenal origin was 1.4 percent (range 0.5 to 2.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/4\">",
"     4",
"    </a>",
"    ]. By comparison, the fractional excretion of magnesium in those with renal magnesium loss was 15 percent (range of 4 to 48 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normomagnesemic magnesium depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of normomagnesemic magnesium depletion (in which there is isolated cellular magnesium depletion) should be considered as a possible cause of refractory hypokalemia or unexplained hypocalcemia in patients at high risk for magnesium loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link&amp;anchor=H8#H8\">",
"     \"Signs and symptoms of magnesium depletion\", section on 'Normomagnesemic magnesium depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One suggested method to detect underlying magnesium depletion is to demonstrate reduced excretion (less than 80 percent over 24 hours) of an infused magnesium load (2.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of lean body weight given over the initial four hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. However, the utility of this test is uncertain. Patients with malnutrition, cirrhosis, diarrhea, or long-term diuretic use typically have a positive test, whether or not they have signs or symptoms referable to magnesium depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/7\">",
"     7",
"    </a>",
"    ]. It seems prudent, therefore, to simply administer magnesium to these patients if they have unexplained hypocalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypokalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The route and dose of magnesium repletion should be selected on the basis of the severity of the clinical manifestations and the degree of hypomagnesemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22105169\">",
"    <span class=\"h2\">",
"     Patients with severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic patients, such as those with tetany, arrhythmias, or seizures should receive intravenous magnesium. Such patients should have continuous cardiac monitoring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the acute setting, hemodynamically unstable patients (including those with arrhythmias consistent with torsade de pointes or hypomagnesemic hypokalemia), 1 to 2 g",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (8 to 16 meq [4 to 8 mmol]) can be given initially over two to fifteen minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H20#H20\">",
"       \"Acquired long QT syndrome\", section on 'Acute therapy of TdP'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H8647773#H8647773\">",
"       \"Clinical manifestations and treatment of hypokalemia\", section on 'Hypomagnesemia and redistributive hypokalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In hemodynamically stable patients with severe symptomatic hypomagnesemia (less than or equal to 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.4",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or 0.8",
"      <span class=\"nowrap\">",
"       meq/L]),",
"      </span>",
"      1 to 2 grams of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (8 to 16 meq [4 to 8 mmol]) in 50 to 100 mL of 5 percent dextrose in water can be given initially over 5 to 60 minutes followed by an infusion (infusion described in the following bullet) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A simple infusion regimen for nonemergent repletion is 4 to 8 g",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (32 to 64 meq [16 to 32 mmol]) given slowly over 12 to 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/9\">",
"       9",
"      </a>",
"      ]. This dose can be repeated as necessary to maintain the plasma magnesium concentration above 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or 0.8",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      &nbsp;In the normomagnesemic patient with hypocalcemia, it has been suggested to repeat this dose daily for three to five days [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with renal insufficiency (creatinine clearance less than 30",
"      <span class=\"nowrap\">",
"       mL/min/1.73m2)",
"      </span>",
"      are at risk for severe hypermagnesemia if large doses of magnesium are given because plasma magnesium concentrations are regulated solely by renal excretion. Thus, we reduce the intravenous magnesium dose in such patients by 50 percent or more and closely monitoring magnesium concentrations. (See",
"      <a class=\"local\" href=\"#H94929816\">",
"       'Treating patients with impaired renal function'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes and treatment of hypermagnesemia\", section on 'Renal failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children, we use a slow infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      ; the dose is 25 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.2 to 0.4",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"      [0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mmol/kg])",
"      </span>",
"      with a maximum single dose of 2 g (16 meq [8 mmol]) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=see_link\">",
"       \"Significance of hypomagnesemia in cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (Conversion relationships: 1 mmol = 2 meq = 24 mg of elemental magnesium = 240 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnesium concentration should be measured 6 to 12 hours after each dose of intravenous magnesium. Repeat doses are given based upon the follow-up measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1055449\">",
"    <span class=\"h3\">",
"     Inefficiency of intravenous magnesium supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It must be appreciated that plasma magnesium concentration inhibits magnesium reabsorption in the loop of Henle, the major site of active magnesium transport. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    .) Thus, when an intravenous magnesium infusion is given, an abrupt but temporary elevation in the plasma magnesium concentration will partially inhibit the stimulus to magnesium reabsorption in the loop of Henle. Thus, up to 50 percent of the infused magnesium will be excreted in the urine. In addition, magnesium uptake by the cells is slow and therefore adequate repletion requires sustained correction of the hypomagnesemia.",
"   </p>",
"   <p>",
"    Because of the inefficiencies of intravenous magnesium just described, oral replacement therapy should be given to asymptomatic patients whenever the oral route of administration is available and oral magnesium supplements can be tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22105176\">",
"    <span class=\"h2\">",
"     Patients with no or minimal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;If available and tolerable, oral replacement should be given to the hypomagnesemic patient with no or minimal symptoms. However, many patients are unable to take oral magnesium or have side effects such as gastrointestinal discomfort and diarrhea. Thus, many hospitalized patients with hypomagnesemia are given intravenous rather than oral magnesium supplementation, even if symptoms are minimal or absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691295\">",
"    <span class=\"h3\">",
"     Oral repletion if available and tolerable",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of oral magnesium salts are available. Each differs in the content of elemental magnesium, but all suffer from limited bioavailability. A typical daily dose in a patient with normal renal function is 240 to 1000 mg (20 to 80 meq [10 to 40 mmol]) of elemental magnesium in divided doses.",
"   </p>",
"   <p>",
"    Sustained-release preparations have the advantage that they are slowly absorbed and thereby minimize renal excretion of the administered magnesium. Available sustained release preparations include:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/22/24933?source=see_link\">",
"     magnesium chloride",
"    </a>",
"    containing 64 to 71.5 mg elemental magnesium (eg, Mag Delay&trade;, Slow-Mag&reg;) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/22/11620?source=see_link\">",
"     magnesium L-lactate",
"    </a>",
"    containing 84 mg elemental magnesium (eg, Mag-Tab SR&reg;). Six to eight tablets (30 to 56 meq [15 to 28 mmol]) should be taken daily in divided doses for severe magnesium depletion. Two to four tablets (10 to 28 meq [5 to 14 mmol]) may be sufficient for mild hypomagnesemia. The use of sustained-release preparations may permit the use of lower doses, which minimizes the associated diarrhea (the major dose limiting side effect).",
"   </p>",
"   <p>",
"    If a sustained release preparation is",
"    <strong>",
"     not",
"    </strong>",
"    available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"     magnesium oxide",
"    </a>",
"    800 to 1600 mg (20 to 40 mmol [40 to 80 meq]) daily in divided doses may be used for moderate to severe hypomagnesemia. Diarrhea frequently occurs with magnesium oxide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691302\">",
"    <span class=\"h3\">",
"     Intravenous repletion in stable hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some hospitalized patients, oral magnesium supplementation may be unavailable or not tolerable (eg, in postoperative patients who cannot take medications orally). Even if such patients with hypomagnesemia are asymptomatic or minimally symptomatic, intravenous magnesium therapy can be used.",
"   </p>",
"   <p>",
"    For routine intravenous repletion or maintenance in the inpatient setting, we use the following regimen in which the dose and rate of repletion depends upon the plasma magnesium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]: severe depletion (eg, &lt;1.0",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    moderate (1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and mild (1.6 to 1.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    combined with suspicion of magnesium depletion) with an estimated repletion dose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the plasma magnesium is less than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or 0.8",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      give 4 to 8 grams (32 to 64 meq [16 to 32 mmol]) over 12 to 24 hours, and repeat as needed.&nbsp;",
"     </li>",
"     <li>",
"      If the plasma magnesium is 1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.4 to 0.6",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or 0.8 to 1.2",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      give 2 to 4 grams (16 to 32 meq [8 to 16 mmol]) over 4 to 12 hours.",
"     </li>",
"     <li>",
"      If the plasma magnesium is 1.6 to 1.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.7 to 0.8",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or 1.4 to 1.6",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      give 1 to 2 grams (8 to 16 meq [4 to 8 mmol]) over one to two hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22105183\">",
"    <span class=\"h2\">",
"     Correction of the underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying disease should also be corrected, if possible. Patients with hypomagnesemia induced by a thiazide or loop diuretic who cannot discontinue diuretic therapy may benefit from the addition of a potassium-sparing diuretic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    . These drugs may decrease magnesium excretion by increasing its reabsorption in the distal nephron [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11254/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=see_link\">",
"     \"Diuretics and magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    also may be helpful in conditions associated with persistent urinary magnesium wasting such as Bartter or Gitelman syndrome or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    nephrotoxicity. In these settings, magnesium repletion alone may be relatively ineffective, since raising the plasma magnesium concentration will, as mentioned above, lead to increased magnesium excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94929816\">",
"    <span class=\"h2\">",
"     Treating patients with impaired renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, great caution should be exercised in treating patients who have acute or chronic kidney injury with magnesium containing medications. However, patients with reduced kidney function may require magnesium repletion if they have severe hypomagnesemia (ie, &lt;1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or 0.8",
"    <span class=\"nowrap\">",
"     meq/L]).",
"    </span>",
"   </p>",
"   <p>",
"    There are no published data to guide therapy in such patients, and it is critical that the plasma magnesium concentration be followed closely (ie, after each magnesium dose). In addition, the patient should be monitored for signs of hypermagnesemia such as facial flushing, decreased tendon reflexes, hypotension, and atrioventricular block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of published data, we take the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <strong>",
"       symptomatic",
"      </strong>",
"      patient who has moderately reduced kidney function (ie, estimated glomerular filtration rate of 15 to 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ) and severe hypomagnesemia should be treated with 2 to 4 g of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      given slowly over 4 to 12 hours. The plasma magnesium should be checked prior to subsequent doses, and daily if doses are given less frequently.",
"     </li>",
"     <li>",
"      <strong>",
"       Asymptomatic",
"      </strong>",
"      patients who have severe hypomagnesemia and moderately decreased kidney function may be treated with approximately half the dose of the selected oral preparation that is recommended for the patient with normal renal function. The plasma magnesium concentration should be measured before giving a subsequent dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It would be extremely unusual for a patient with no kidney function (ie, on dialysis) to have severe magnesium depletion in the absence of an extrarenal loss such as diarrhea. In such cases, treating the diarrhea may be sufficient to correct the hypomagnesemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H959166297\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypomagnesemia should be suspected in patients who have risk factors for hypomagnesemia (eg, chronic diarrhea, proton pump inhibitor therapy, alcoholism, diuretic use) or clinical manifestations of hypomagnesemia (eg, unexplained hypocalcemia, refractory hypokalemia, neuromuscular disturbances, ventricular arrhythmias). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an etiology is not apparent from the history, gastrointestinal and renal losses may be distinguished by measuring the 24-hour urinary magnesium excretion or the fractional excretion of magnesium on a random urine specimen (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?7/50/7970?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?17/59/18354?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). The daily excretion of more than 10 to 30 mg or a fractional excretion of magnesium above 2 percent in a patient with normal renal function indicates renal magnesium wasting. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normomagnesemic magnesium depletion, or isolated cellular magnesium depletion, may be a cause of refractory hypokalemia or unexplained hypocalcemia. Normomagnesemic magnesium depletion may be detected by demonstrating reduced excretion of an infused magnesium load. Alternatively, magnesium may be empirically administered to patients at high risk for magnesium depletion who have unexplained hypocalcemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypokalemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Normomagnesemic magnesium depletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The route of magnesium repletion varies with the severity of the clinical manifestations. Patients with severe signs and symptoms of hypomagnesemia should receive intravenous magnesium with cardiac monitoring. Oral replacement should be given to the asymptomatic outpatient, preferably with a sustained-release preparation, in order to prevent abrupt elevations in the plasma magnesium concentration. (See",
"      <a class=\"local\" href=\"#H22105169\">",
"       'Patients with severe symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22105176\">",
"       'Patients with no or minimal symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The underlying disease should also be corrected, if possible. Patients with hypomagnesemia due to renal losses may benefit from the addition of a potassium-sparing diuretic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H22105183\">",
"       'Correction of the underlying disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, patients with reduced kidney function should not receive magnesium-containing medications. However, patients with moderately reduced kidney function who have severe hypomagnesemia may require magnesium repletion. The appropriate regimen for magnesium repletion in such patients depends upon the presence or absence of signs and symptoms of hypomagnesemia. It is critical that the plasma magnesium be followed closely (ie, after each dose), and the patient be monitored for signs of hypermagnesemia. (See",
"      <a class=\"local\" href=\"#H94929816\">",
"       'Treating patients with impaired renal function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5270798\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Zalman Agus, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/1\">",
"      Weisinger JR, Bellor&iacute;n-Font E. Magnesium and phosphorus. Lancet 1998; 352:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/2\">",
"      Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999; 10:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/3\">",
"      al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1994; 24:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/4\">",
"      Elisaf M, Panteli K, Theodorou J, Siamopoulos KC. Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. Magnes Res 1997; 10:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/5\">",
"      Ryzen E, Nelson TA, Rude RK. Low blood mononuclear cell magnesium content and hypocalcemia in normomagnesemic patients. West J Med 1987; 147:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/6\">",
"      H&eacute;bert P, Mehta N, Wang J, et al. Functional magnesium deficiency in critically ill patients identified using a magnesium-loading test. Crit Care Med 1997; 25:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/7\">",
"      Ryzen E, Elbaum N, Singer FR, Rude RK. Parenteral magnesium tolerance testing in the evaluation of magnesium deficiency. Magnesium 1985; 4:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/8\">",
"      Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/9\">",
"      Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 2005; 62:1663.",
"     </a>",
"    </li>",
"    <li>",
"     Gunn V, Nechyba C. The Harriet Lane Handbook 16th Ed: Formulary. Mosby 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/11\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/12\">",
"      Reed BN, Zhang S, Marron JS, Montague D. Comparison of intravenous and oral magnesium replacement in hospitalized patients with cardiovascular disease. Am J Health Syst Pharm 2012; 69:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11254/abstract/13\">",
"      Dai LJ, Raymond L, Friedman PA, Quamme GA. Mechanisms of amiloride stimulation of Mg2+ uptake in immortalized mouse distal convoluted tubule cells. Am J Physiol 1997; 272:F249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 834 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11254=[""].join("\n");
var outline_f10_63_11254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H959166297\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normomagnesemic magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22105169\">",
"      Patients with severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1055449\">",
"      - Inefficiency of intravenous magnesium supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22105176\">",
"      Patients with no or minimal symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691295\">",
"      - Oral repletion if available and tolerable",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691302\">",
"      - Intravenous repletion in stable hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22105183\">",
"      Correction of the underlying disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94929816\">",
"      Treating patients with impaired renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H959166297\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5270798\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?7/50/7970?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of magnesium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?17/59/18354?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of magnesium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=related_link\">",
"      Causes and treatment of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=related_link\">",
"      Diuretics and magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=related_link\">",
"      Significance of hypomagnesemia in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11255="Meperidine (pethidine): Pediatric drug information";
var content_f10_63_11255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meperidine (pethidine): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"    see \"Meperidine (pethidine): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/46/24293?source=see_link\">",
"    see \"Meperidine (pethidine): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Demerol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Demerol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"      see \"Meperidine (pethidine): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate analgesic effect;",
"     <b>",
"      when changing route of administration, note that oral doses are about half as effective as parenteral dose",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M., I.V., SubQ: Usual: 1-1.5 mg/kg/dose every 3-4 hours as needed; 1-2 mg/kg as a single dose preoperative medication may be used; maximum dose: 100 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. continuous infusion: Loading dose: 0.5-1 mg/kg followed by initial rate: 0.3 mg/kg/hour; titrate dose to effect; may require 0.5-0.7 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Oral, I.M., I.V.: SubQ: 50-150 mg/dose every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     AHCPR dosing guidelines: Opioid naive patients:",
"     <b>",
"      Note:",
"     </b>",
"     Oral route not recommended (Carr, 1992; Jacox, 1994):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adults &lt;50 kg: Moderate to severe pain: I.M., I.V., SubQ: Usual initial dose: 0.75 mg/kg every 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adults &ge;50 kg: Moderate to severe pain: I.M., I.V., SubQ: Usual initial dose: 100 mg every 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Use with caution and reduce dose; accumulation of meperidine and its active metabolite (normeperidine) may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use with caution and reduce dose; accumulation of meperidine and its active metabolite (normeperidine) may occur",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 25 mg/mL (1 mL); 50 mg/mL (1 mL [DSC]); 100 mg/mL (1 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Demerol&reg;: 25 mg/mL (1 mL); 25 mg/0.5 mL (0.5 mL); 50 mg/mL (1 mL, 1.5 mL, 2 mL, 30 mL); 75 mg/mL (1 mL); 100 mg/mL (1 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [for PCA pump]: 10 mg/mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 50 mg/5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Demerol&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Demerol&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F192786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with water; dilute oral liquid in water prior to use (use 4 oz water for adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Suitable for occasional use; when repeated doses are required, the I.M. route of administration is preferred",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow I.V. push: Do not administer rapid I.V., administer over at least 5 minutes and dilute to &le;10 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent infusion: Dilute to 1 mg/mL and administer over 15-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F192793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amikacin, ampicillin, ampicillin/sulbactam, anidulafungin, aztreonam, bivalirudin, bumetanide, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chloramphenicol, cisatracurium, cladribine, clindamycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxycycline, droperidol, eptifibatide, erythromycin lactobionate, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gallium nitrate, gemcitabine, gentamicin, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, insulin (regular), kanamycin, labetalol, lidocaine, linezolid, magnesium sulfate, melphalan, methyldopate, methylprednisolone sodium succinate, metoclopramide, metoprolol, metronidazole, micafungin, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pemetrexed, penicillin G potassium, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, propranolol, ranitidine, remifentanil, sargramostim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, verapamil, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, doxorubicin liposome, idarubicin, imipenem/cilastatin, micafungin, minocycline.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, ceftriaxone, furosemide, nafcillin, nesiritide, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, atropine with hydroxyzine, atropine with promethazine, butorphanol, chlorpromazine, cimetidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, ketamine, metoclopramide, midazolam, ondansetron, pentazocine, pentazocine with perphenazine, prochlorperazine edisylate, promethazine, ranitidine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone, furosemide, heparin, morphine, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diazepam.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incompatible with aminophylline, heparin, phenobarbital, phenytoin, and sodium bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate to severe pain; adjunct to anesthesia and preoperative sedation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Meperidine may be confused with meprobamate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Demerol&reg; may be confused with Demulen&reg;, Desyrel, Dilaudid&reg;, Pamelor&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avoid the use of meperidine for pain control, especially in elderly and renally-compromised patients because of the risk of neurotoxicity (American Pain Society, 2008; Institute for Safe Medication Practices [ISMP], 2007)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F192792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, circulatory depression, hypotension, palpitation, shock, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, delirium, disorientation, dizziness, drowsiness, dysphoria, euphoria, fatigue, flushing, hallucinations, headache, intracranial pressure increased, lightheadedness, malaise, mental depression, nervousness, paradoxical CNS stimulation, restlessness, sedation, seizure (associated with metabolite accumulation), serotonin syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, biliary spasm, constipation, nausea, paralytic ileus, sphincter of Oddi spasm, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ureteral spasms, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (including pain, wheal, and flare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle twitching, myoclonus, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, respiratory arrest, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, histamine release, hypersensitivity reactions, physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to meperidine or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pulmonary, hepatic, or renal disorders; use with caution in patients with tachycardias, biliary colic, seizure disorders, or those receiving prolonged use or high-dose meperidine [normeperidine (an active metabolite and CNS stimulant) may accumulate and precipitate twitches, tremors, or seizures]; decrease the dose in patients with renal or hepatic impairment (normeperidine metabolite may accumulate in these patients);",
"     <b>",
"      Note:",
"     </b>",
"     Due to the accumulation of normeperidine and its adverse effects, meperidine is not considered to be an opioid of choice for the treatment of pain. The Institute for Safe Medication Practices (ISMP) recommends avoiding its use for pain control, especially in the elderly and in patients with renal impairment (ISMP, 2007). The American Pain Society (2003) recommends that meperidine should not be used for chronic pain control; if used for treatment of acute pain it should only be used in patients without renal or CNS disease, treatment should be limited to &le;48 hours, and (adult) doses should not exceed 600 mg/24 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution and decrease initial dose in patients with sickle cell anemia, Addison's disease, hypothyroidism, urethral stricture, prostatic hypertrophy, or pheochromocytoma (meperidine may precipitate hypertension in patients with pheochromocytoma). Meperidine may obscure diagnosis or clinical course of patients with acute abdominal conditions. Safe use in pregnancy prior to labor has not been established; when administered to a pregnant woman, meperidine passes into the fetal circulation and may result in respiratory and CNS depression in the newborn; resuscitative equipment and naloxone should be available for the neonate.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS and respiratory depression may occur. Neonates and young infants may be at higher risk for adverse effects, especially respiratory depression (due to decreased elimination); use with caution and in reduced doses in this age group. Use with great caution (and only if essential) in patients with head injury, increased ICP, or other intercranial lesions (potential to depress respiration and increase ICP may be greatly exaggerated in these patients). Use with extreme caution in patients with COPD, cor pulmonale, acute asthmatic attacks, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve. Severe hypotension may occur; use with caution in postoperative patients, in patients with hypovolemia, or in those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Meperidine may be given I.V., but should be administered very slowly and as a diluted solution; rapid I.V. administration may result in increased adverse effects including severe respiratory depression, apnea, hypotension, peripheral circulatory collapse, or cardiac arrest; do not administer I.V. unless a narcotic antagonist and respiratory support are immediately available.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms or seizures. Warn patient of possible impairment of alertness or physical coordination and orthostatic hypotension. Interactions with other CNS drugs may occur. Healthcare provider should be alert to problems of abuse, misuse, and diversion. Infants born to women physically dependent on opioids will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Multiple dose vial may contain sulfites which may cause allergic reactions in susceptible individuals; oral liquid may contain benzoic acid or sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use meperidine products containing benzoic acid or sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F803880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Meperidine. Management: Consider a decrease in meperidine dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F192747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Meperidine is known to cross the placenta, which may result in respiratory or CNS depression in the newborn.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status; relief of pain, level of sedation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M., SubQ: Within 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M., SubQ: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5-7 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M., SubQ: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: Preterm 1-7 days: 8.8 L/kg; term 1-7 days: 5.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: 1 week to 2 months: 8 L/kg; 3-18 months: 5 L/kg; 5-8 years: 2.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 3-4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: (to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 52%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 3-18 months: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: &sim;60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via hydrolysis and N-demethylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &sim;50% to 60%, increased bioavailability with liver disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preterm infants 3.6-65 days of age: 11.9 hours (range: 3.3-59.4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Term infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.3-4 days of age: 10.7 hours (range: 4.9-16.8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     26-73 days of age: 8.2 hours (range: 5.7-31.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 23 hours (range: 12-39 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 3-18 months: 2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-8 years: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with liver disease: 7-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normeperidine (active metabolite): Neonates: 30-85 hours; Adults: 8-16 hours; normeperidine half-life is dependent on renal function and can accumulate with high doses or in patients with decreased renal function; normeperidine may precipitate tremors or seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;5% meperidine eliminated unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/46/24293?source=see_link\">",
"      see \"Meperidine (pethidine): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and the herbal medicine St John's wort. May cause dry mouth. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May cause postural hypotension (use caution when changing position from lying or sitting to standing).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Equianalgesic doses: morphine 10 mg I.M. = meperidine 75-100 mg I.M..",
"     <b>",
"      Note",
"     </b>",
"     : Although meperidine has been used in combination with chlorpromazine and promethazine as a premedication (&ldquo;Lytic Cocktail&rdquo;), this combination may have a higher rate of adverse effects compared to alternative sedatives and analgesics (American Academy of Pediatrics Committee on Drugs, 1995)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Reappraisal of Lytic Cocktail/Demerol&reg;, Phenergan&reg;, and Thorazine&reg; (DPT) for the Sedation of Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(4):598-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11255/abstract-text/7700765 /pubmed\" id=\"7700765 \" target=\"_blank\">",
"        7700765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carr D, Jacox A, Chapman CR, et al, &ldquo;Clinical Practice Guideline Number 1: Acute Pain Management: Operative or Medical Procedures and Trauma,&rdquo; Rockville, Maryland: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Publication No 92-0032, 1992.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cole TB, Sprinkle RH, Smith SJ, et al, &ldquo;Intravenous Narcotic Therapy for Children With Severe Sickle Cell Pain Crisis,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1986, 140(12):1255-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11255/abstract-text/3776942/pubmed\" id=\"3776942\" target=\"_blank\">",
"        3776942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice, &ldquo;High Alert Medication Feature: Reducing Patient Harm From Opiates,&rdquo; ISMP Medication Safety Alert, February 22, 2007. Available at file://www.ismp.org/Newsletters/acutecare/articles/20070222.asp.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacox A, Carr D, Payne R, et al, &ldquo;Clinical Practice Guideline Number 9: Management of Cancer Pain,&rdquo; Rockville, Maryland: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Publication No. 94-0592, 1994.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(5):385-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11255/abstract-text/7614777 /pubmed\" id=\"7614777 \" target=\"_blank\">",
"        7614777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pokela ML, Olkkola KT, Koivisto ME, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Intravenous Meperidine in Neonates and Infants,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1992, 52(4):342-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11255/abstract-text/1424407/pubmed\" id=\"1424407\" target=\"_blank\">",
"        1424407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Principles of Analgesic Use in the Treatment of Acute Pain and Chronic Cancer Pain,\" 5th ed, Glenview, IL: American Pain Society, 2003.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12580 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11255=[""].join("\n");
var outline_f10_63_11255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192763\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192764\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053810\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053803\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192737\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192720\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192786\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053815\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192793\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053806\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053814\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192795\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192792\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053819\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053802\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053801\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803880\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192729\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192732\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192747\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053809\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053800\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053817\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053818\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053808\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053820\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12580|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=related_link\">",
"      Meperidine (pethidine): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/46/24293?source=related_link\">",
"      Meperidine (pethidine): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11256="Acenocoumarol: Drug information";
var content_f10_63_11256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acenocoumarol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/32/518?source=see_link\">",
"    see \"Acenocoumarol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sintrom&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F854984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant, Coumarin Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F855019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage must be individualized. The following information is based on the manufacturer's labeling in Canada.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention/treatment of thrombosis/embolism:",
"     </b>",
"     Oral: Initial: 8-12 mg on day 1, followed by 4-8 mg on day 2. Subsequent dosage should be based on PT/INR measurements. Usual range of maintenance doses: 1-10 mg/day. Tapering of dosage is recommended prior to discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2525054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; lower dosages may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12851253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; the manufacturer labeling does not provide specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12851252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; the manufacturer labeling does not provide specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sintrom&reg;: 1 mg, 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11215944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F855021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F854985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders; atrial fibrillation with risk of embolism; adjunct in the prophylaxis of coronary occlusion and transient ischemic attacks",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F855004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Interferes with hepatic synthesis of vitamin K-dependent coagulation factors (II, VII, IX, X)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F854995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     As with all anticoagulants, bleeding is the major adverse effect of acenocoumarol. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic:  Skin necrosis (including hemorrhagic forms) (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Priapism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hemorrhage may occur at virtually any site; sites that may be predisposed to bleeding include CNS (brain), eye, GI tract (melena), liver and gall bladder (hematobilia), urogenital tract (hematuria), uterus (metrorrhagia, menorrhagia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Reactions observed with similar coumarin derivatives:  Alopecia (reversible, rare), appetite decreased, diarrhea, gangrene (rare), hypersensitivity/allergic reactions (dermatitis, fever, urticaria), nausea, purple toe syndrome (rare), vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F854990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acenocoumarol, related coumarin derivatives, or any component of the formulation; hemorrhagic tendencies and/or blood dyscrasias (eg, hemophilia, thrombocytopenic purpura, leukemia); recent or potential surgery of the eye or CNS; major regional lumbar block anesthesia or surgery resulting in large, open surfaces; bleeding from the GI, respiratory, or GU tract; aneurysm (cerebral or dissecting aortic); cerebrovascular hemorrhage; recent surgical procedures resulting in increased fibrinolytic activity (eg, surgery of the lung, prostate, uterus); polyarthritis; diverticulitis; emaciation; malnutrition; severe hypertension; severe parenchymal lesions of the liver and kidneys; pericarditis or pericardial effusion; subacute bacterial endocarditis; ascorbic acid deficiency;  uncooperative patient (eg, alcoholic, unsupervised senile, or psychotic) intramuscular injections; inadequate laboratory facilities; threatened abortion; eclampsia/pre-eclampsia; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F854991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity: May cause hypersensitivity reactions, including anaphylaxis; use with caution in patients with anaphylactic disorders. Cross-reactivity among coumarin anticoagulants has been described.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: May cause major or fatal bleeding. Risk factors for bleeding include high intensity anticoagulation (INR &gt;4), age (&gt;65 years), variable INRs, history of GI bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, severe diabetes, malignancy, trauma, renal insufficiency, polycythemia vera, vasculitis, open wound, history of PUD, indwelling catheters, menstruating and postpartum women, drug-drug interactions and long duration of therapy or known genetic deficiency in CYP2C9 activity. Patient must be instructed to report bleeding, accidents, or falls as well as any new or discontinued medications, herbal or alternative products used, significant changes in smoking or dietary habits. Unrecognized bleeding sites (eg, colon cancer) may be uncovered by anticoagulation. Treatment should be withdrawn at the earliest signs of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin necrosis/gangrene: Necrosis or gangrene of the skin and other tissues can occur (rarely) due to early hypercoagulability; risk is increased in patients with protein C or S deficiency. Onset is usually within the first few days of therapy and is frequently localized to the limbs, breast, or penis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; \"Purple toe&rdquo; syndrome:  \"Purple toe&rdquo; syndrome, due to cholesterol microembolization, has been described with coumarin-type anticoagulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dietary insufficiency: Use with caution in patients with prolonged dietary insufficiencies (vitamin K deficiency).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Use with caution in patients with acute infection or active TB; antibiotics and fever may alter response to acenocoumarol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment (undergoes hepatic metabolism).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly may be more sensitive to anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovulating women: May be at risk of developing ovarian hemorrhage at the time of ovulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with genomic variants in CYP2C9 and/or VKORC1: Presence of the CYP2C9*3 allele and/or polymorphism of the vitamin K oxidoreductase (VKORC1) gene may increase the risk of bleeding. Lower doses may be required in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient selection: Use care in the selection of patients appropriate for this treatment; ensure patient cooperation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F855003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C19 (minor), CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F855002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Androgens: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents: May enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Alitretinoin; Altretamine; Aminoglutethimide; Anastrozole; Asparaginase (E. coli); Asparaginase (Erwinia); AzaCITIDine; Bleomycin; Capecitabine; CARBOplatin; Carmustine; Chlorambucil; CISplatin; Cladribine; Cytarabine (Conventional); Cytarabine (Liposomal); Dacarbazine; DACTINomycin; DAUNOrubicin (Conventional); DAUNOrubicin (Liposomal); Denileukin Diftitox; DOCEtaxel; DOXOrubicin (Liposomal); EPIrubicin; Estramustine; Etoposide Phosphate; Exemestane; Fludarabine; Goserelin; Hydroxyurea; IDArubicin; Irinotecan; Letrozole; Leuprolide; Lomustine; Mechlorethamine; Megestrol; MitoMYcin (Systemic); MitoXANtrone; Nilutamide; PACLitaxel; Pegaspargase; Pentostatin; Polyestradiol; Porfimer; RiTUXimab; Streptozocin; Tamoxifen; Temozolomide; Teniposide; Thioguanine; Thiotepa; Topotecan; Toremifene; Tretinoin (Systemic); Valrubicin; VinBLAStine; Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bicalutamide: May increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloral Hydrate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coenzyme Q-10: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products. Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cranberry: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desvenlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dicloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Vitamin K Antagonists may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received oral anticoagulants within 1 week or have INR 3 or greater.  Monitor for bleeding and immediately stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Vitamin K Antagonists. Efavirenz may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Ophthalmic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethacrynic Acid: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethotoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin. Management: Anticoagulant dose adjustment will likely be necessary when ethotoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenugreek: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the adverse/toxic effect of Vitamin K Antagonists. Management: Consider avoiding the use of this combination of agents. Monitor for signs and symptoms of bleeding if vitamin K antagonists and Ginkgo biloba are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucagon: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glutethimide: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May enhance the adverse/toxic effect of Vitamin K Antagonists. Particularly, the risk of bleeding may be increased due to possible antiplatelet effects of green tea. Green Tea may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivermectin (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lansoprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents.  Monitor for increased INR/bleeding risk if metronidazole is initiated/dose increased, or decreased effects if metronidazole is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miconazole (Topical): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milnacipran: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the anticoagulant effect of Vitamin K Antagonists. Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neomycin: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the anticoagulant effect of Vitamin K Antagonists. NSAID (COX-2 Inhibitor) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phytonadione: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Salsalate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfinpyrazone [Off Market]: May decrease the metabolism of Vitamin K Antagonists. Sulfinpyrazone [Off Market] may decrease the protein binding of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vorinostat: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F855007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol. Acute ethanol ingestion (binge drinking) decreases the metabolism of oral anticoagulants and increases PT/INR. Chronic daily ethanol use increases the metabolism of oral anticoagulants and decreases PT/INR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Vitamin K can reverse the anticoagulation effects of acenocoumarol; large amounts of food high in vitamin K (such as beef liver, pork liver, green tea, and green leafy vegetables) may reverse acenocoumarol, decrease prothrombin time, and lead to therapeutic failure. Patients should not change dietary habits once stabilized on acenocoumarol therapy. A balanced diet with a consistent intake of vitamin K is essential.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High doses of vitamin A, E, or C may alter PT; use caution with fish oils or omega-3 fatty acids; cranberry juice or other cranberry products may increase the INR in patients receiving a similar agent (warfarin) and cause severe bleeding (flavonoids found in cranberries may inhibit cytochrome P450 isoenzyme CYP2C9 which metabolize warfarin).  Similar risks might be anticipated with acenocoumarol as it also undergoes CYP2C9 metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease oral anticoagulant levels. Alfalfa contains large amounts of vitamin K as do many enteral products. Coenzyme Q",
"     <sub>",
"      10",
"     </sub>",
"     may decrease response to oral anticoagulants. Avoid cat's claw, dong quai, evening primrose, feverfew, red clover, horse chestnut, garlic, green tea, ginseng, and ginkgo (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F854986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acenocoumarol crosses the placenta. Teratogenic effects have been reported with coumarin derivative anticoagulants following first trimester exposure and may include coumarin embryopathy (nasal hypoplasia and/or stippled epiphyses; limb hypoplasia may also be present).  Adverse events to the fetus have also been observed following second and third trimester exposure with coumarin derivative anticoagulants and may include CNS abnormalities (including ventral midline dysplasia, dorsal midline dysplasia). Fatal hemorrhage in the fetus has been reported even when the mother&rsquo;s acenocoumarol levels were in the therapeutic range. Acenocoumarol should not be used during pregnancy because of significant risks. Women of childbearing potential are advised to use effective contraception during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12850980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small quantities of acenocoumarol can be detected in breast milk and undesirable effects in nursing infants are not anticipated. The manufacturer recommends prophylaxis therapy with phytonadione (1 mg administered once weekly) and monitoring of the infant for signs of bleeding. The American College of Chest Physicians (ACCP) considers acenocoumarol to be safe to use in breast-feeding women (Guyatt,  2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F855020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Foods high in vitamin K (eg, beef liver, pork liver, green tea, and leafy green vegetables) inhibit anticoagulant effect. Do not change dietary habits once stabilized on acenocoumarol therapy. A balanced diet with a consistent intake of vitamin K is essential. Avoid large amounts of alfalfa, asparagus, broccoli, Brussels sprouts, cabbage, cauliflower, green teas, kale, lettuce, spinach, turnip greens, watercress; these decrease efficacy of oral anticoagulants. It is recommended that an adult diet contain a",
"     <b>",
"      consistent",
"     </b>",
"     vitamin K content of 75-120 mcg/day. Check with healthcare provider before changing diet. Avoid using multivitamins that contain vitamin K.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F855023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     PT/INR (",
"     <b>",
"      Note:",
"     </b>",
"     To obtain a valid PT in patients receiving heparin, allow 4-5 hours after last I.V. dose and 12-24 hours after last SubQ dose before blood is drawn); hepatic function, CBC, urinalysis (for albuminuria/proteinuria)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acenox (CN);",
"     </li>",
"     <li>",
"      Acitrom (IN);",
"     </li>",
"     <li>",
"      Neo-Sintrom (CN);",
"     </li>",
"     <li>",
"      Nistrom (IN);",
"     </li>",
"     <li>",
"      Sinthrome (GB);",
"     </li>",
"     <li>",
"      Sintrom (AR, AT, BE, BG, CH, FR, GR, IL, IT, MX, NL, PT, PY);",
"     </li>",
"     <li>",
"      Syncumar (HN, PL, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F855261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic synthesis of coagulation factors II, VII, IX, and X, as well as proteins C and S, requires the presence of vitamin K. These clotting factors are biologically activated by the addition of carboxyl groups to key glutamic acid residues within the proteins&rsquo; structure. In the process, &ldquo;active&rdquo; vitamin K is oxidatively converted to an &ldquo;inactive&rdquo; form, which is then subsequently reactivated by vitamin K epoxide reductase complex 1 (VKORC1). Coumarins are thought to inhibit VKORC1, thus depleting functional vitamin K reserves and hence reduce synthesis of active clotting factors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F855011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Peak anticoagulant effect: Oral: 36-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :  0.16-0.34 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via oxidation: R-enantiomer (by CYP2C9 [primary], 1A2, and 2C19; S-enantiomer primarily by CYP2C9) and via keto-reduction to inactive metabolites; also undergoes nitro-reduction via gut flora. (Thijssen, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: R-enantiomer: ~11 hours; S-enantiomer: &lt;2 hours (Thijssen, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (60% as metabolites; minimal amount as unchanged drug); feces (29% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11256/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suvarna R, Pirmohamed M, and Henderson L, &ldquo;Possible Interaction Between Warfarin and Cranberry Juice,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2003, 327(7429):1454.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11256/abstract-text/14684645/pubmed\" id=\"14684645\" target=\"_blank\">",
"        14684645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      T&agrave;ssies D, Freire C, Pijoan J, et al, &ldquo;Pharmacogenetics of Acenocoumarol: Cytochrome P450 CYP 2C9 Polymorphisms Influence Dose Requirements and Stability of Anticoagulation,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2002, 87(11):1185-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11256/abstract-text/12414349/pubmed\" id=\"12414349\" target=\"_blank\">",
"        12414349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teichert M, van Schaik RH, Hofman A, et al, &ldquo;Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2009, 85(4):379-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11256/abstract-text/19225451/pubmed\" id=\"19225451\" target=\"_blank\">",
"        19225451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thijssen HH, Janssen GM, and Baars LG, &ldquo;Lack of Effect of Cimetidine on Pharmacodynamics and Kinetics of Single Oral Doses of R- and S-Acenocoumarol,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1986, 30(5):619-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11256/abstract-text/3758150/pubmed\" id=\"3758150\" target=\"_blank\">",
"        3758150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thijssen HH, Flinois JP, and Beaune PH, &ldquo;Cytochrome P4502C9 is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2000, 28(11):1284-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11256/abstract-text/11038154/pubmed\" id=\"11038154\" target=\"_blank\">",
"        11038154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Touloupidis S, Zoumpos I, Kalaitzis C, et al, &ldquo;Acenocoumarol Associated Priapism: Report of a Case,&rdquo;",
"      <i>",
"       Andrologia",
"      </i>",
"      , 2004, 36(1):47-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11256/abstract-text/14871265/pubmed\" id=\"14871265\" target=\"_blank\">",
"        14871265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9159 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11256=[""].join("\n");
var outline_f10_63_11256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854980\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854984\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855019\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525054\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851253\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851252\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950003\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11215944\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855021\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854985\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855004\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854995\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854990\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854991\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855003\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855002\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855007\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854986\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12850980\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855020\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855023\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869446\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855261\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855011\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9159|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/32/518?source=related_link\">",
"      Acenocoumarol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11257="Bortezomib: Drug information";
var content_f10_63_11257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bortezomib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/23/14709?source=see_link\">",
"    see \"Bortezomib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Velcade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Velcade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Proteasome Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Consecutive doses should be separated by at least 72 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma (first-line therapy; in combination with melphalan and prednisone):",
"     </b>",
"     I.V., SubQ: 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day treatment cycle for 4 cycles, followed by 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, 22, and 29 of a 42-day treatment cycle for 5 cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative first-line therapy (unlabeled dosing):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CyBorD regimen: I.V.: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, 15, and 22 of a 28-day treatment cycle for 4 cycles (may continue beyond 4 cycles) in combination with cyclophosphamide and dexamethasone (Khan, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients &ge;65 years: I.V.: 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, 15, and 22 of a 35-day treatment cycle, in combination with",
"     <b>",
"      either",
"     </b>",
"     melphalan and prednisone or melphalan, prednisone, and thalidomide (Boccadoro, 2010; Bringhen, 2010; Palumbo, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma (relapsed) and mantle cell lymphoma:",
"     </b>",
"     I.V., SubQ: 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice weekly for 2 weeks on days 1, 4, 8, and 11 of a 21-day treatment cycle. Therapy extending beyond 8 cycles may be administered by the standard schedule or may be given once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest (days 23 through 35).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cutaneous or peripheral T-cell lymphoma, relapsed/refractory (unlabeled use):",
"     </b>",
"     I.V.: 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice weekly for 2 weeks on days 1, 4, 8, and 11 of a  21-day treatment cycle (Zinzani, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Follicular lymphoma, relapsed/refractory (unlabeled use):",
"     </b>",
"     I.V.: 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 4, 8, and 11 of a 28-day treatment cycle, in combination with bendamustine and rituximab for 6 cycles (Friedberg, 2011)",
"     <b>",
"      or",
"     </b>",
"     1.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, 15, and 22 of a 35-day treatment cycle, in combination with bendamustine and rituximab for 5 cycles (Fowler, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic light-chain amyloidosis (unlabeled use):",
"     </b>",
"     I.V.: 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 4, 8, and 11 of a 21-day treatment cycle (with or without dexamethasone) (Kastritis, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Waldenstr&ouml;m&rsquo;s macroglobulinemia, relapsed/refractory  (unlabeled use):",
"     </b>",
"     I.V.: 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 4, 8, and 11 of a 21-day treatment cycle (Chen, 2007)",
"     <b>",
"      or",
"     </b>",
"     1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with dexamethasone and rituximab) (Treon, 2009)",
"     <b>",
"      or",
"     </b>",
"     1.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, and 15 of a 28-day treatment cycle (in combination with rituximab) (Ghobrial, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2655956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F142141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary. Dialysis may reduce bortezomib concentrations; administer postdialysis (Leal, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F142142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (bilirubin &le;1 times ULN and AST &gt;UNL or bilirubin &gt;1-1.5 times ULN):  No initial dose adjustment necessary (LoRusso, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate (bilirubin &gt;1.5-3 times ULN) and severe impairment (bilirubin &gt;3 times ULN):  Reduce initial dose to 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in the first cycle; based on patient tolerance, may consider dose escalation to 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (LoRusso, 2012) or further dose reduction to 0.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subsequent cycles",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F142157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myeloma (first-line therapy):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets should be &ge;70,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ANC should be  &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,  and nonhematologic toxicities should resolve to grade 1 or baseline prior to therapy initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets &le;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or ANC &le;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     on bortezomib day(s) (except day 1): Withhold bortezomib; if several bortezomib doses in consecutive cycles are withheld, reduce dose 1 level (1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose reduced to 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose reduced to 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade &ge;3 nonhematological toxicity (other than neuropathy): Withhold bortezomib until toxicity resolves to grade 1 or baseline. May reinitiate bortezomib at 1 dose level reduction (1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose reduced to 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose reduced to 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuropathic pain and/or peripheral sensory or motor neuropathy: See \"Neuropathic pain and/or peripheral sensory or motor neuropathy\" toxicity adjustment guidelines below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Relapsed multiple myeloma and mantle cell lymphoma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 3 nonhematological (excluding neuropathy) or Grade 4 hematological toxicity: Withhold until toxicity resolved; may reinitiate with a 25% dose reduction (1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose reduced to 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose reduced to 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuropathic pain and/or peripheral sensory or motor neuropathy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider subQ administration in patients with pre-existing or at high risk for peripheral neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 1 (asymptomatic; deep tendon reflex loss or paresthesia) without pain or loss of function: No action needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental activities of daily living):  Reduce dose to 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 2 with pain or Grade 3 (severe symptoms; limiting self-care activities of daily living): Withhold until toxicity resolved, may reinitiate at 0.7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 4 (life-threatening consequences with urgent intervention indicated): Discontinue therapy",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Velcade&reg;: 3.5 mg [contains mannitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F142120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The reconstituted concentrations for I.V. and SubQ administration are different; use caution when calculating the volume for each dose. Consider SubQ administration in patients with pre-existing or at high risk for peripheral neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer via rapid I.V. push (3-5 seconds)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Subcutaneous administration of bortezomib 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 4, 8, and 11 of a 21-day treatment cycle has been studied in a limited number of patients with relapsed multiple myeloma; doses were administered subcutaneously (concentration of 2.5 mg/mL) into the thigh or abdomen, rotating the injection site with each dose; injections at the same site within a single cycle were avoided (Moreau, 2010; Moreau, 2011). Response rates were similar to I.V. administration; decreased incidence of grade 3 or higher adverse events were observed with SubQ administration. Administer at least 1 inch from an old site and never administer to tender, bruised, erythematous, or indurated sites.  If injection site reaction occurs, the more dilute 1 mg/mL concentration may be used SubQ (or I.V. administration of 1 mg/mL concentration may be considered).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      For I.V. or SubQ administration only; fatalities have been reported with inadvertent intrathecal administration.",
"     </b>",
"     Bortezomib should",
"     <b>",
"      NOT",
"     </b>",
"     be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of multiple myeloma; treatment of relapsed or refractory mantle cell lymphoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F3017256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of relapsed/refractory cutaneous T-Cell lymphomas (mycosis fungoides), relapsed/refractory follicular lymphoma, relapsed/refractory peripheral T-cell lymphoma, systemic light-chain amyloidosis, relapsed/refractory Waldenstr&ouml;m&rsquo;s macroglobulinemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bortezomib may be confused with carfilzomib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The reconstituted concentrations for I.V. and SubQ administration are different; use caution when calculating the volume for each dose. The manufacturer provides stickers to facilitate identification of the route for reconstituted vials.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       For I.V. or SubQ administration only.  Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should",
"       <b>",
"        NOT",
"       </b>",
"       be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location",
"       <b>",
"        away",
"       </b>",
"       from the separate storage location recommended for intrathecal medications. Bortezomib should",
"       <b>",
"        NOT",
"       </b>",
"       be delivered to the patient at the same time with any medications intended for intrathecal administration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions and incidences reported are associated with monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (7% to 52%), fever (8% to 35%), headache (10% to 19%), dizziness (10% to 18%; excludes vertigo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (12% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (19% to 52%), nausea (16% to 52%), constipation (25% to 30%), vomiting (9% to 29%), anorexia (14% to 21%), abdominal pain (11%), appetite decreased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (30% to 34%; grade 3: 5% to 24%; grade 4: 3% to 7%; nadir: Day 11; recovery: By day 21), neutropenia (10% to 27%; grade 3: 8% to 14%; grade 4: 2% to 4%; nadir: Day 11; recovery: By day 21), anemia (19% to 23%; grade 3: 4% to 6%; grade 4: &lt;1%), leukopenia (18% to 20%; grade 3: 5%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (SubQ 37%; I.V. 35% to 54%; grade &ge;2: 24% to 39%; grade 3: SubQ 5%; I.V. 7% to 14%; grade 4: 1%), neuralgia (23%), paresthesia (7% to 19%), weakness (7% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac disorder (treatment emergent; 8%), hypotension (8%; grades 3/4: 2%), heart failure (&le;1%; includes acute pulmonary edema, cardiac failure, congestive cardiac failure, cardiogenic shock)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (&ge;grade 3: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site irritation (SubQ 6%; I.V. 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Herpes zoster (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute diffuse infiltrative pulmonary disease, acute respiratory distress syndrome (ARDS), alkaline phosphatase increased, amyloidosis, anaphylaxis, angina, angina pectoris, angioedema, ascites, aspergillosis, atelectasis, atrial fibrillation exacerbation, atrial flutter, AV block, bacteremia, blindness, bone pain, bradycardia, cardiac amyloidosis, cardiac arrest, cardiac tamponade, cardiopulmonary arrest, catheter-related infection, cerebral hemorrhage, cerebrovascular accident, coma, conjunctival infection/irritation, cranial palsy, deep vein thrombosis, diplopia, disseminated intravascular coagulation (DIC), duodenitis (hemorrhagic), dysarthria, dysautonomia, dysgeusia, dyspepsia, dysphagia, edema, embolism, encephalopathy, epistaxis, fecal impaction, gastritis (hemorrhagic), gastroenteritis, gastroesophageal reflux, GGT increased, glomerular nephritis, hearing impairment, hematemesis, hematuria, hemoptysis, hemorrhagic cystitis, hepatic failure, hepatic hemorrhage, hepatitis, hepatocellular damage, herpes meningoencephalitis, hyperbilirubinemia, hyper-/hypoglycemia, hyper-/hypokalemia, hyper-/hyponatremia, hypersensitivity, hyperuricemia, hypocalcemia, hypoxia, ileus, interstitial pneumonia, intestinal perforation, intracerebral hemorrhage, ischemic colitis, ischemic stroke, laryngeal edema, left ventricular ejection fraction decreased, leukocytoclastic vasculitis, limb pain, listeriosis, lymphopenia, melena, MI, myalgia, myocardial ischemia, nasopharyngitis, neutropenic fever, ophthalmic herpes, optic neuritis, oral candidiasis, oral mucosal petechiae, pancreatitis, paralytic ileus, pericardial effusion, pericarditis, peritonitis, phlebitis, pleural effusion, pneumonitis, portal vein thrombosis, posterior reversible encephalopathy syndrome (PRES), proliferative glomerular nephritis, pruritus, psychosis, pulmonary embolism, pulmonary hypertension, pulmonary infiltrate, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, renal failure, respiratory failure, respiratory insufficiency, respiratory tract infection, seizure, sepsis, septic shock, SIADH, sinus arrest, sinusitis, spinal cord compression, Stevens-Johnson syndrome, stomatitis, stroke (hemorrhagic), subarachnoid hemorrhage, subdural hematoma, suicidal ideation, Sweet's syndrome (acute febrile neutrophilic dermatosis), syncope, tachycardia, torsade de pointes, toxic epidermal necrolysis, toxoplasmosis, transaminases increased, transient ischemic attack, tumor lysis syndrome, ventricular tachycardia, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (excluding local reactions) to bortezomib, boron, mannitol, or any component of the formulation; administration via the intrathecal route",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Hematologic toxicity, including neutropenia and severe thrombocytopenia may occur; risk is increased in patients with pretreatment platelet counts &lt;75,000/&mu;L; frequent monitoring is required throughout treatment; may require dosage or schedule adjustments; withhold treatment for platelets &lt;30,000/&mu;L. Nadirs generally occur following the last dose of a cycle and recover prior to the next cycle. Hemorrhage (gastrointestinal and intracerebral) due to low platelet count has been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Has been associated with the development or exacerbation of heart failure (HF) and decreased left ventricular ejection fraction (LVEF); monitor closely in patients with risk factors for HF or existing heart disease, although HF and decreased LVEF have been observed in patients without risk factors. Has also been associated with isolated reports of  QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Nausea, vomiting, diarrhea, or constipation may occur; may require antiemetics or antidiarrheals. Ileus may occur. Administer fluid and electrolytes to prevent dehydration; interrupt therapy for severe symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Acute liver failure has been reported (rarely) in patients receiving multiple concomitant medications and with serious underlying conditions. Hepatitis, transaminase increases, and hyperbilirubinemia have also been reported; interrupt therapy to assess reversibility. Use caution in patients with hepatic dysfunction; reduced initial doses are recommended for moderate and severe hepatic impairment (exposure is increased); closely monitor for toxicities. Limited data exists for patients that have been rechallenged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Herpes reactivation: Herpes (zoster and simplex) reactivation has been reported with bortezomib; consider antiviral prophylaxis during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension (including postural and orthostatic); use caution with dehydration, history of syncope, or medications associated with hypotension (may require adjustment of antihypertensive medication, hydration, and mineralocorticoids and/or sympathomimetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: May cause or worsen peripheral neuropathy (usually sensory but may be mixed sensorimotor); risk may be increased with previous use of neurotoxic agents or pre-existing peripheral neuropathy (in patients with pre-existing neuropathy, use only after risk versus benefit assessment); monitor for signs and symptoms; adjustment of dose and/or schedule may be required. The incidence of grades 2 and 3 peripheral neuropathy may be lower with SubQ route (compared to I.V.); consider subQ administration in patients with pre-existing or at high risk for peripheral neuropathy. The majority of patients with &ge;grade 2 peripheral neuropathy have improvement in or resolution of symptoms with dose adjustments or discontinuation. In a study of elderly patients receiving a weekly bortezomib schedule with combination chemotherapy, the incidence of peripheral neuropathy was significantly reduced without an effect on outcome (Boccadoro, 2010; Palumbo, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Posterior reversible leukoencephalopathy syndrome (PRES, formerly RPLS): Has been reported (rarely). Symptoms of PRES include confusion, headache, hypertension, lethargy, seizure, blindness and/or other vision, or neurologic disturbances; discontinue bortezomib if PRES occurs. MRI is recommended to confirm PRES diagnosis. The safety of reinitiating bortezomib in patients previously experiencing PRES is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Pulmonary disorders (some fatal) including pneumonitis, interstitial pneumonia, lung infiltrates, and acute respiratory distress syndrome (ARDS) have been reported. Pulmonary hypertension (without left heart failure or significant pulmonary disease) has been reported rarely. Promptly evaluate with new or worsening cardiopulmonary symptoms; therapy interruption may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome has been reported with bortezomib; risk is increased in patients with high tumor burden prior to treatment; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Hyper- and hypoglycemia may occur in diabetic patients receiving oral hypoglycemics; monitor; may require adjustment of diabetes medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Coadministration of strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir) may increase bortezomib exposure; monitor for signs of toxicity and consider dose reduction if concurrent therapy cannot be avoided. Efficacy may be reduced when administered with strong CYP3A4 inducers (eg, rifampin); concomitant use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      For I.V. or SubQ administration only.",
"     </b>",
"     Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should",
"     <b>",
"      NOT",
"     </b>",
"     be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location",
"     <b>",
"      away",
"     </b>",
"     from the separate storage location recommended for intrathecal medications. Bortezomib should",
"     <b>",
"      NOT",
"     </b>",
"     be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (moderate), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May diminish the therapeutic effect of Bortezomib. Management: Patients should avoid taking vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy.  It is probably unnecessary to advise patients to avoid foods/beverages that contain vitamin C (e.g., citrus fruits, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Bortezomib.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dexamethasone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May diminish the antineoplastic effect of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins with bortezomib.  It is probably unnecessary to restrict or limit vitamin C-containing foods/beverages.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3017257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food:  Avoid grapefruit juice (may increase bortezomib levels).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease bortezomib levels). Avoid green tea and green tea extracts (may diminish the therapeutic effect of bortezomib) (Golden, 2009). Avoid ascorbic acid supplements, including  multivitamins containing ascorbic acid (may diminish bortezomib activity) during treatment, especially 12 hours before and after bortezomib treatment (Perrone, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F142126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects (fetal loss and decreased fetal weight) were observed in animal reproduction studies at doses less than the equivalent human dose (based on BSA). Women of reproductive potential should avoid becoming pregnant and should use effective contraception during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F142146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F142127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6894443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Green tea and green tea extracts may diminish the therapeutic effect of bortezomib and should be avoided (Golden, 2009). Avoid grapefruit juice. Avoid additional, nondietary sources of ascorbic acid supplements, including multivitamins containing ascorbic acid (may diminish bortezomib activity) during treatment, especially 12 hours before and after bortezomib treatment (Perrone, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Velcade Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5 mg (1): $1848.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (monitor frequently throughout therapy); liver function tests (in patients with existing hepatic impairment); signs/symptoms of peripheral neuropathy, dehydration, hypotension, or PRES; renal function, pulmonary function (with new or worsening pulmonary symptoms)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F142128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Velcade (AR, AT, AU, BB, BE, BG, BM, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, MT, MX, MY, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, RU, SE, SG, SK, SR, TH, TR, TT, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bortezomib inhibits proteasomes, enzyme complexes which regulate protein homeostasis within the cell. Specifically, it reversibly inhibits chymotrypsin-like activity at the 26S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 498-1884 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; distributes widely to peripheral tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic primarily via CYP2C19 and 3A4 and to a lesser extent CYP1A2; forms metabolites (inactive) via deboronization followed by hydroxylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Single dose: I.V.: 9-15 hours; multiple dosing: 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : 40-193 hours; 1.3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : 76-108 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agathocleous A, Rohatiner A, Rule S, et al, &ldquo;Weekly Versus Twice Weekly Bortezomib Given in Conjunction With Rituximab, in Patients With Recurrent follicular Lymphoma, Mantle Cell Lymphoma and Waldenstr&ouml;m Macroglobulinaemia,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2010, 151(4):346-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20880120/pubmed\" id=\"20880120\" target=\"_blank\">",
"        20880120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andre P, Cisternino S, Chiadmi F, et al, &ldquo;Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(9):1462-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/15985470/pubmed\" id=\"15985470\" target=\"_blank\">",
"        15985470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arnulf B, Pylypenko H, Grosicki S, et al, &ldquo;Updated survival Analysis of a Randomized, Phase 3 Study of Subcutaneous versus Intravenous Bortezomib in Patients With Relapsed Multiple Myeloma,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2012, 97(12):1925-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/22689676/pubmed\" id=\"22689676\" target=\"_blank\">",
"        22689676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boccadoro M, Bringhen S, Gaidano G, et al, &ldquo;Bortezomib, Melphalan, Prednisone, and Thalidomide (VMPT) Followed by Maintenance With Bortezomib and Thalidomide (VT) for Initial Treatment of Elderly Multiple Myeloma Patients,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(7s):8013 [abstract 8013 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bringhen S, Larocca A, Rossi D, et al, &ldquo;Efficacy and Safety of Once-Weekly Bortezomib in Multiple Myeloma Patients,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(23):4745-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/ 20807892/pubmed\" id=\" 20807892\" target=\"_blank\">",
"        20807892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cavo M, Pantani L, Petrucci MT, et al, &ldquo;Bortezomib-Thalidomide-Dexamethasone Is Superior to Thalidomide-Dexamethasone as Consolidation Therapy After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 120(1):9-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/22498745/pubmed\" id=\"22498745\" target=\"_blank\">",
"        22498745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cavo M, Tacchetti P, Patriarca F, et al, &ldquo;Bortezomib With Thalidomide Plus Dexamethasone Compared With Thalidomide Plus Dexamethasone as Induction Therapy Before, and Consolidation Therapy After, Double Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Randomised Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9758):2075-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/21146205/pubmed\" id=\"21146205\" target=\"_blank\">",
"        21146205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chanan-Khan AA, Kaufman JL, Mehta J, et al, &ldquo;Activity and Safety of Bortezomib in Multiple Myeloma Patients With Advanced Renal Failure: A Multicenter Retrospective Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 109(9):2604-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/17138816/pubmed\" id=\"17138816\" target=\"_blank\">",
"        17138816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chanan-Khan A, Sonneveld P, Schuster MW, et al, \"Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(29):4784-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/18711175/pubmed\" id=\"18711175\" target=\"_blank\">",
"        18711175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen CI, Kouroukis CT, White D, et al, &ldquo;Bortezomib is Active in Patients With Untreated or Relapsed Waldenstrom's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(12):1570-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/17353550/pubmed\" id=\"17353550\" target=\"_blank\">",
"        17353550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos MA, Mateos MV, Richardson PG, et al, &ldquo;Risk Factors for, and Reversibility of, Peripheral Neuropathy Associated With Bortezomib-Melphalan-Prednisone in Newly Diagnosed Patients With Multiple Myeloma: Subanalysis of the Phase 3 VISTA Study,&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2011, 86(1):23-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/21146205/pubmed\" id=\"21146205\" target=\"_blank\">",
"        21146205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos MA, Richardson PG, Schlag R, et al, &ldquo;VMP (Bortezomib, Melphalan, and Prednisone) is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(36):6086-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/19858394/pubmed\" id=\"19858394\" target=\"_blank\">",
"        19858394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engelhardt M, Udi J, Kleber M, et al, &ldquo;European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European Experts Meeting on Multiple Myeloma,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2010, 51(11):2006-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20807087/pubmed\" id=\"20807087\" target=\"_blank\">",
"        20807087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher RI, Bernstein SH, Kahl BS, et al, &ldquo;Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(30):4867-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/17001068/pubmed\" id=\"17001068\" target=\"_blank\">",
"        17001068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fowler N, Kahl BS, Lee P, et al, &ldquo;Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(25):3389-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/21810687/pubmed\" id=\"21810687\" target=\"_blank\">",
"        21810687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedberg JW, Vose JM, Kelly JL, et al, &ldquo;The Combination of Bendamustine, Bortezomib, and Rituximab for  Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(10):2807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/21239695/pubmed\" id=\"21239695\" target=\"_blank\">",
"        21239695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghobrial IM, Hong F, Padmanabhan S, et al, &ldquo;Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(8):1422-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20142586/pubmed\" id=\"20142586\" target=\"_blank\">",
"        20142586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbar PJ and Seger AC, &ldquo;Fatalities Resulting From Accidental Intrathecal Administration of Bortezomib: Strategies for Prevention,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(27):3427-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/22851559/pubmed\" id=\"22851559\" target=\"_blank\">",
"        22851559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golden EB, Lam PY, Kardosh A, et al, &ldquo;Green Tea Polyphenols Block the Anticancer Effects of Bortezomib and Other Boronic Acid-Based Proteasome Inhibitors,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(23):5927-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/19190249/pubmed\" id=\"19190249\" target=\"_blank\">",
"        19190249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harousseau JL, Attal M, Avet-Loiseau H, et al, &ldquo;Bortezomib Plus Dexamethasone is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone as Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(30):4621-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20823406/pubmed\" id=\"20823406\" target=\"_blank\">",
"        20823406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harousseau JL, Palumbo A, Richardson PG, et al, &ldquo;Superior Outcomes Associated With Complete Response in Newly Diagnosed Multiple Myeloma Patients Treated With Nonintensive Therapy: Analysis of the Phase 3 VISTA Study of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(19):3743-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20628153/pubmed\" id=\"20628153\" target=\"_blank\">",
"        20628153",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iwamoto T, Ishibashi M, Fujieda A, et al, &ldquo;Drug Interaction Between Itraconazole and Bortezomib: Exacerbation of Peripheral Neuropathy and Thrombocytopenia Induced by Bortezomib,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(7):661-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20575631/pubmed\" id=\"20575631\" target=\"_blank\">",
"        20575631",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, &ldquo;American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jagannath S, Barlogie B, Berenson JR, et al, &ldquo;Bortezomib in Recurrent and/or Refractory Multiple Myeloma; Initial Clinical Experience in Patients With Impaired Renal Function,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 103(6):1195-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/15690325/pubmed\" id=\"15690325\" target=\"_blank\">",
"        15690325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kastritis E, Anagnostopoulos A, Bamias A, et al, &ldquo;Reversibility of Renal Failure in Newly Diagnosed Patients With Multiple Myeloma Treated With High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 108(11):3586 [abstract 3586 from 2006 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kastritis E, Wechalekar AD, Dimopoulos MA, et al, &ldquo;Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(6):1031-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20085941/pubmed\" id=\"20085941\" target=\"_blank\">",
"        20085941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan ML, Reeder CB, Kumar SK, et al, &ldquo;A Comparison of Lenalidomide/Dexamethasone versus Cyclophosphamide/Lenalidomide/Dexamethasone versus Cyclophosphamide/Bortezomib/Dexamethasone in Newly Diagnosed Multiple Myeloma,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2012, 156(3):326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/22107129/pubmed\" id=\"22107129\" target=\"_blank\">",
"        22107129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lamm W, Willenbacher W, Lang A, et al, \"Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis,\"",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2011, 90(2):201-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20821326/pubmed\" id=\"20821326\" target=\"_blank\">",
"        20821326",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leal TB, Remick SC, Takimoto CH, et al, &ldquo;Dose-Escalating and Pharmacological Study of Bortezomib in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study,&rdquo;",
"      <i>",
"       Cancer Chemother Pharamcol",
"      </i>",
"      , 2011, 68(6):1439-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/21479634/pubmed\" id=\"21479634\" target=\"_blank\">",
"        21479634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al, &ldquo;Pharmacokinetics and Safety of Bortezomib in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2012, 18(10):2954-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/22394984/pubmed\" id=\"22394984\" target=\"_blank\">",
"        22394984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mateos MV, Richardson PG, Schlag R, et al, &ldquo;Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-up and Impact of Subsequent Therapy in the Phase III VISTA Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(13):2259-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20368561/pubmed\" id=\"20368561\" target=\"_blank\">",
"        20368561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mikhael JR, Belch AR, Prince HM, et al, &ldquo;High Response Rate to Bortezomib With or Without Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Results of a Global Phase 3b Expanded Access Program,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2009, 144(2):169-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/19036114/pubmed\" id=\"19036114\" target=\"_blank\">",
"        19036114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moreau P, Coiteux V, Hulin C, et al, &ldquo;Prospective Comparison of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2008, 93(12):1908-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/18768528/pubmed\" id=\"18768528\" target=\"_blank\">",
"        18768528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moreau P, Pylypenko H, Grosicki S, et al, &ldquo;A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients With Relapsed Multiple Myeloma,",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):312 [abstract 312 from 2010 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moreau P, Pylypenko H, Grosicki S, et al, \"Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Relapsed Multiple Myeloma: A Randomised, Phase 3, Non-Inferiority Study,\"",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(5):431-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/21507715/pubmed\" id=\"21507715\" target=\"_blank\">",
"        21507715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor OA, Wright J, Moskowitz C, et al &ldquo;Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(4):676-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/15613699/pubmed\" id=\"15613699\" target=\"_blank\">",
"        15613699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orlowski RZ, Nagler A, Sonneveld P, et al, \"Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(25):3892-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/17679727/pubmed\" id=\"17679727\" target=\"_blank\">",
"        17679727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Bringhen S, Rossi D, et al, &ldquo;Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance With Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(22):128 [abstract 128 from ASH 2009 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pekol T, Daniels JS, Labutti J, et al, &ldquo;Human Metabolism of the Proteasome Inhibitor Bortezomib: Identification of Circulating Metabolites,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2005, 33(6):771-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/15764713/pubmed\" id=\"15764713\" target=\"_blank\">",
"        15764713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrone G, Hideshima T, Ikeda H, et al, &ldquo;Ascorbic Acid Inhibits Activity of Bortezomib",
"      <i>",
"       in vivo",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2009, 23(9):1679-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/19369963/pubmed\" id=\"19369963\" target=\"_blank\">",
"        19369963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reece DE, Hegenbart U, Sanchorawala V, et al, \"Efficacy and Safety of Once-Weekly and Twice-Weekly Bortezomib in Patients With Relapsed Systemic AL Amyloidosis: Results of a Phase 1/2 Study,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/21562045/pubmed\" id=\"21562045\" target=\"_blank\">",
"        21562045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reeder CB, Reece DE, Kukreti V, et al, &ldquo;Once- versus Twice-Weekly Bortezomib Induction Therapy With CyBorD in Newly Diagnosed Multiple Myeloma,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(16):3416-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20413666/pubmed\" id=\"20413666\" target=\"_blank\">",
"        20413666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Sonneveld P, Schuster M, et al, &ldquo;Extended Follow-up of a Phase 3 Trial in Relapsed Multiple Myeloma: Final Time-to-Event Results of the APEX Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(10):3557-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/17690257/pubmed\" id=\"17690257\" target=\"_blank\">",
"        17690257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Sonneveld P, Schuster MW, et al, &ldquo;Reversibility of Symptomatic Peripheral Neuropathy With Bortezomib in the Phase III APEX Trial in Relapsed Multiple Myeloma: Impact of a Dose-Modification Guideline,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2009, 144(6):895-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/19170677/pubmed\" id=\"19170677\" target=\"_blank\">",
"        19170677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Sonneveld P, Schuster MW, et al, &ldquo;Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      ,  2005, 352(24):2487-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/15958804/pubmed\" id=\"15958804\" target=\"_blank\">",
"        15958804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      San-Miguel JF, Richardson PG, Sonneveld P, et al, &ldquo;Efficacy and Safety of Bortezomib in Patients With Renal Impairment: Results from the APEX Phase 3 Study,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2008, 22(4):842-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/18200040/pubmed\" id=\"18200040\" target=\"_blank\">",
"        18200040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      San Miguel JF, Schlag R, Khuageva N, et al, &ldquo;Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(9):906-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/18753647/pubmed\" id=\"18753647\" target=\"_blank\">",
"        18753647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al, &ldquo;Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(24):2946-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/22802322/pubmed\" id=\"22802322\" target=\"_blank\">",
"        22802322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treon SP, Ioakimidis L, Soumerai JD, et al, &ldquo;Primary Therapy of Waldenstr&ouml;m Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(23):3830-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/19506160/pubmed\" id=\"19506160\" target=\"_blank\">",
"        19506160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uttamsingh V, Lu C, Miwa G, et al, &rdquo;Relative Contributions of the Five Major Hyman Cytochromes P450, 1A2, 2C9, 2C19, and 3A4, to the Hepatic Metabolism of the Proteosome Inhibitor Bortezomib,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2005, 33(11):1723-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/16103134/pubmed\" id=\"16103134\" target=\"_blank\">",
"        16103134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanderloo JP, Pomplun ML, Vermeulen LC, et al, &ldquo;Stability of Unused Reconstituted Bortezomib in Original Manufacturer Vials,&rdquo;",
"      <i>",
"       J Oncol Pharm Pract",
"      </i>",
"      , 2011, 17(4):400-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/20926455/pubmed\" id=\"20926455\" target=\"_blank\">",
"        20926455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zinzani PL, Musuraca G, Tani M, et al, &ldquo;Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(27):4293-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/63/11257/abstract-text/17709797/pubmed\" id=\"17709797\" target=\"_blank\">",
"        17709797",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8509 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11257=[""].join("\n");
var outline_f10_63_11257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142137\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855139\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142156\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142140\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2655956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142141\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142142\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142157\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142118\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142106\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142120\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142119\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017256\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401586\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142154\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142123\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142108\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142150\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142112\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017257\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142114\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142126\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142146\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142127\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6894443\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323023\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142116\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142128\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142107\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142122\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/23/14709?source=related_link\">",
"      Bortezomib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11258="Management of coronary heart disease in women";
var content_f10_63_11258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of coronary heart disease in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/63/11258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11258/contributors\">",
"     Pamela S Douglas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/63/11258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11258/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/63/11258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/63/11258/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/63/11258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular diseases are the most common cause of death and disability in women in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although there has been a reduction in the death rate from coronary heart disease (CHD) since 1980 (",
"    <a class=\"graphic graphic_figure graphicRef77937 \" href=\"UTD.htm?9/52/10062\">",
"     figure 1",
"    </a>",
"    ), CHD still accounted for 35 percent of all-cause mortality in women in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/2\">",
"     2",
"    </a>",
"    ]. Between the ages of 45 to 64, one in nine women develops symptoms of some form of cardiovascular disease. After age 65, the ratio climbs to one in three women, according to the National Center for Health Statistics.",
"   </p>",
"   <p>",
"    There are significant differences between men and women in the epidemiology, diagnosis, treatment and prognosis of CHD that should be taken into account in the care of women with known or suspected disease (",
"    <a class=\"graphic graphic_figure graphicRef79678 graphicRef51374 \" href=\"UTD.htm?22/18/22831\">",
"     figure 2A-B",
"    </a>",
"    ). Unfortunately, data from clinical trials about the management of women with an acute coronary syndrome (myocardial infarction or unstable angina) are limited, since women are generally underrepresented in randomized controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, most available data suggest that women are not referred as often as men for appropriate diagnostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapeutic procedures, (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Coronary reperfusion'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A repeating theme that will be described below is that unadjusted outcomes are often worse in women than men. However, with issues such as an early invasive strategy in non-ST elevation syndromes, fibrinolytic therapy or primary percutaneous coronary intervention in ST elevation myocardial infarction, and percutaneous coronary intervention in general, these differences are almost entirely due to confounding risk factors (eg, older age, more diabetes, more hypertension), not female sex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of CHD in women will be reviewed here. The clinical features, including diagnosis of CHD in women, the outcome after acute myocardial infarction (AMI), and the problem of CHD in young women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=see_link\">",
"     \"Clinical features and diagnosis of coronary heart disease in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28217?source=see_link\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success rate of therapy for CHD is similar in women and men; however, the complication rates differ, resulting in a sex specific profile of benefit (see below). The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    Task Force recommended that women with unstable angina or non-ST segment elevation MI be treated in a similar manner to men with the same indications for noninvasive and invasive testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/9\">",
"     9",
"    </a>",
"    ]. The one exception is the absence of evidence of benefit of glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in women with unstable angina. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'GP IIb/IIIa inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs are used in the treatment of CHD. Women are more likely to receive nitrates, calcium channel blockers, diuretics, and sedatives than men, while some studies suggest that women are less likely to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers and statins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. In a review of almost 3800 patients with stable angina in the Euro Heart Survey, women were as likely to be treated with a beta blocker as men, but significantly less likely to be treated with aspirin (73 versus 81 percent) and a statin (45 versus 51 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hormone replacement therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for cardiac protection in women with CHD since the HERS trials showed no evidence of benefit (",
"    <a class=\"graphic graphic_figure graphicRef62591 \" href=\"UTD.htm?22/34/23085\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, ongoing clinical trials are investigating the possible value of different hormone formulations and the earlier initiation of therapy in the perimenopausal period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used for secondary prevention of CHD, an overview of randomized trials from the Antiplatelet Trialists' Collaboration found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 162",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was beneficial in women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/18\">",
"     18",
"    </a>",
"    ]. Among patients with an acute coronary syndrome (ACS), aspirin (162 to 325 mg) should be part of initial management of all patients, both men and women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not as well studied for primary prevention as in men,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may provide the same benefit in women with at least one risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/19\">",
"     19",
"    </a>",
"    ]. Aspirin was also studied in women at average risk in the Women's Healthy Study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/20\">",
"     20",
"    </a>",
"    ]. Low-dose aspirin in women appears to produce a similar or even greater reduction in platelet reactivity than seen in men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/21\">",
"     21",
"    </a>",
"    ] and, in the Women's Health Study, the reductions in thromboxane and prostacyclin concentrations were similar to those in men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/20\">",
"     20",
"    </a>",
"    ]. Nevertheless, the data suggest benefit against stroke but not MI in younger women, with a significant reduction in MI in women &ge;65 years of age that was similar to the reported benefit in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of beta blockers after myocardial infarction (MI) is well demonstrated in women and is at least equivalent to that in men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of angiotensin converting enzyme (ACE) inhibition after acute MI have been demonstrated in a number of trials that included some women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/24\">",
"     24",
"    </a>",
"    ]. Although efficacy in women has not been specifically studied, the criteria for ACE inhibitor therapy should be the same as in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been demonstrated that patients at high risk for cardiovascular disease, as defined by the HOPE trial, have improved survival when treated with an ACE inhibitor. However, it is likely that this benefit is due to blood pressure reduction rather than a specific effect of ACE inhibition. Specific data are not available for women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyses of the four trials of lipid lowering for secondary prevention in different patient populations presented below, as well as the JUPITER trial, support a beneficial effect of statins in women with CHD, [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 4S (Scandinavian",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      Survival Study) evaluated 4444 patients with established CHD and baseline plasma total cholesterol levels between 212 and 309",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.5 and 8.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/25\">",
"       25",
"      </a>",
"      ]. The patients were treated with a lipid-lowering diet and then randomly assigned to therapy with placebo or with simvastatin (20 to 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in an attempt to reduce the level of total cholesterol below 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Among the 827 women in this trial, there was a significant reduction in coronary events in those treated with simvastatin (14.5 versus 21.7 percent); the 34 percent risk reduction was identical to that in men. There were too few deaths among women to evaluate the effect of simvastatin on mortality.",
"     </li>",
"     <li>",
"      The CARE (Cholesterol and Recurrent Events) trial involved 4159 patients with a history of a myocardial infarction in the previous two years; however, these patients did not have markedly elevated cholesterol levels &mdash; the average concentrations of total, LDL and HDL cholesterol of 209",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      139",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and 39",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.4, 3.6, and 1.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/26\">",
"       26",
"      </a>",
"      ]. At five years, overall benefits with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      treatment (40 mg before sleep) compared to placebo included significant reductions in the combined incidence of coronary death and nonfatal MI (10.2 versus 13.2 percent), stroke, and the need for revascularization. These benefits were more pronounced among the 576 postmenopausal women in this trial: 43 percent reduction in coronary death and nonfatal MI and 56 percent reduction in stroke (",
"      <a class=\"graphic graphic_figure graphicRef72888 \" href=\"UTD.htm?10/54/11118\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Heart Protection Study (HPS) randomly assigned 20,536 subjects to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo: 33 percent had baseline LDL cholesterol &lt;116",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;3",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      25 percent had a level of 116 to 135",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3 to 3.5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and 42 percent had levels &gt;135",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;3.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/28\">",
"       28",
"      </a>",
"      ]. Entry criteria included a history of cardiovascular disease, diabetes mellitus, or treated hypertension. After an average follow-up of 5.5 years, treatment with simvastatin resulted in significant reductions in all-cause mortality (12.9 versus 14.7 percent for placebo), deaths from heart disease or related blood vessel disease, and major cardiovascular events. The benefit in women was similar to that seen in men (",
"      <a class=\"graphic graphic_figure graphicRef68116 \" href=\"UTD.htm?6/28/6592\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The PROVE IT-TIMI 22 trial randomly assigned 4162 patients with ACS to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/29\">",
"       29",
"      </a>",
"      ]. Treatment was initiated within 10 days of presentation, but after PCI if one was performed. The median LDL-cholesterol at initiation of therapy was 106",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.74",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      At a mean follow-up of two years, the primary end point (all-cause mortality, MI, UA, revascularization, or stroke) was significantly reduced with atorvastatin (22.4 versus 26.3 percent). The benefit of atorvastatin therapy was more marked in women than in men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NON-ST ELEVATION ACUTE CORONARY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-ST elevation ACS include unstable angina (UA) and non-ST elevation MI (NSTEMI). Women with a non-ST elevation ACS tend to be older than men and have more comorbidities such as diabetes and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with positive biomarkers generally treated the same as men. In contrast, biomarker negative women do not appear to benefit from glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, and may even have an excess of adverse events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Early invasive strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An invasive strategy of early catheterization and revascularization, if indicated, improves the outcome of men with a non-ST elevation acute coronary syndrome (ACS) when compared to a noninvasive approach. There are conflicting data as to whether the benefit of early invasive therapy also applies to women. The favorable effect of early invasive therapy was seen only in men in the FRISC II and RITA 3 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], while similar benefits in men and women were noted in TACTICS-TIMI 18 and a prospective study of 1450 consecutive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=see_link&amp;anchor=H15#H15\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\", section on 'Effect in women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The factors responsible for these conflicting findings are not well understood. A possible contributing factor is that women in FRISC II and RITA 3 were at lower risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]; in such patients, the benefit from revascularization would be less and the procedural risk might be a more important determinant of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/35\">",
"     35",
"    </a>",
"    ]. Consistent with this hypothesis are the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In TACTICS-TIMI 18, women with low TIMI risk scores (0 to 2) or no elevation in serum troponin T had a nonsignificant trend toward a worse outcome with early invasive therapy; men with these features had no benefit but no suggestion of harm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/33\">",
"       33",
"      </a>",
"      ]. Compared to men, women who underwent PCI had a significantly higher risk of major bleeding (8.3 versus 2.9 percent).",
"     </li>",
"     <li>",
"      In FRISC II, the excess risk in women was due to a high mortality rate with CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/31\">",
"       31",
"      </a>",
"      ]. In contrast, the peri-CABG mortality was not so high in TACTICS-TIMI 18 and the above observational study, which contributed to the beneficial effect of early intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Any increase in CABG risk in women is largely related to comorbid conditions (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Bypass surgery'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2007 update from the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force recommended that women with a non-ST elevation MI should be managed in a manner similar to men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/9\">",
"     9",
"    </a>",
"    ]. Women, like men, with high risk features benefit from an early invasive strategy within the first 48 hours. They should also receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . However, biomarker negative women (ie, those with a negative serum troponin) should not receive a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor.",
"   </p>",
"   <p>",
"    Despite these general recommendations and the increase in mortality, in practice women with a non-ST elevation ACS are treated less aggressively than men. In a review from the CRUSADE National Quality Improvement Initiative of almost 36,000 such patients (41 percent women) seen at 391 hospitals in the United States between 2000 and 2002, women were treated less aggressively than men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/5\">",
"     5",
"    </a>",
"    ]. They were significantly less likely to undergo catheterization within 24 hours of admission (42 versus 49 percent in men) and less likely to undergo PCI within this time (44 versus 52 percent). Women had higher rates of in-hospital mortality, reinfarction, and heart failure but, after adjustment, the rates were similar to those in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of the use of glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in patients with non-ST elevation ACS found that benefit was limited to the 38 percent of patients in whom PCI or CABG was performed within 30 days (OR for death or MI 0.89, 95% CI 0.80-0.98) and to those with a positive troponin T or I concentration (&ge;0.1",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    (OR 0.85, 95% CI 0.71-1.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/36\">",
"     36",
"    </a>",
"    ]. There was a significant increase in the primary end point of death or MI in women (11.5 versus 10.4, OR 1.14, 95% CI 1.01-1.3) compared to a benefit in men. However, this difference disappeared when troponin status was included, since men more often presented with positive baseline troponins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H29#H29\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'GP IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ST ELEVATION MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in non-ST elevation ACS, several issues have been raised concerning the management of women with ST elevation MI (STEMI), although women should generally be treated the similarly to men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coronary reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary reperfusion after acute MI can be achieved by fibrinolysis or, preferably, primary percutaneous coronary intervention (PCI), usually performed with stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies, women were somewhat less likely to receive fibrinolysis, even if eligible, and were likely to experience a greater delay in being treated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/6,12,14,37,38\">",
"     6,12,14,37,38",
"    </a>",
"    ]. Although definitive data are not available, it appears that fibrinolysis reduces mortality in acute MI by the same proportion in both sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women receiving fibrinolysis have a higher rate of mortality and morbidity compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/6,7,40-43\">",
"     6,7,40-43",
"    </a>",
"    ]. These differences are primarily due to worse baseline characteristics, such as older age and significantly higher rates of diabetes mellitus, hypertension, and prior heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/6,7,40,42,43\">",
"     6,7,40,42,43",
"    </a>",
"    ]. There are conflicting data as to whether the increase in mortality disappears [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/6\">",
"     6",
"    </a>",
"    ] or persists after correction for these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/7,43\">",
"     7,43",
"    </a>",
"    ]. In a review from GUSTO IIb, for example, there was a nonsignificant trend toward an increased risk of death or infarction at 30 days in women after adjustment for baseline variables (odds ratio 1.27, p = 0.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women have a modestly increased risk of bleeding, including hemorrhagic stroke, after fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/6,42\">",
"     6,42",
"    </a>",
"    ]. An additional bleeding concern is the use of fibrinolytic agents in menstruating women. Data on this issue are limited. Among 12 menstruating women in GUSTO-I, there was no significant increase in severe bleeding compared to nonmenstruating women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/44\">",
"     44",
"    </a>",
"    ]. A significant increase in",
"    <strong>",
"     moderate",
"    </strong>",
"    bleeding was found that was offset by the benefits of fibrinolytic therapy. Thus, menstruating women should not automatically be excluded from fibrinolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women undergoing primary PCI have had higher rates of in-hospital and longer term mortality than men in both retrospective observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/45-48\">",
"     45-48",
"    </a>",
"    ] and subset analyses of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/42,49\">",
"     42,49",
"    </a>",
"    ]. However, as with fibrinolysis, this difference was no longer present on multivariate analysis in almost all of these studies since women tended to be older and to have more comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/42,45,47-50\">",
"     42,45,47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of these effects was illustrated by a review from the CADILLAC trial, which compared primary stenting to primary angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/49\">",
"     49",
"    </a>",
"    ]. At one year, women had significantly higher rates of mortality (7.6 versus 3.0 percent in men), target vessel revascularization (16.7 versus 12.1 percent), and major adverse cardiac events (23.9 versus 15.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/49\">",
"     49",
"    </a>",
"    ]. These differences were largely due to a higher prevalence of clinical risk factors in women (older age and more frequent diabetes, hypertension, and renal insufficiency) and to smaller body size, which may be associated with more frequent procedural complications and perhaps lack of weight adjustment of pharmacologic therapy especially anticoagulants.",
"   </p>",
"   <p>",
"    After adjustment, female sex was not an independent risk factor for mortality in the CADILLAC trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a single center observational study of patients with acute MI treated predominantly with PCI, women had a significantly lower mortality at one year after adjustment for older age and a greater prevalence of diabetes and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible explanation for this finding is a greater benefit from PCI. Support for this hypothesis comes from a study that measured the degree of myocardial salvage after primary PCI in 502 women and 1435 men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/8\">",
"     8",
"    </a>",
"    ]. The amount of myocardium at risk or initial perfusion defect was similar in women and men (22 and 24 percent of the left ventricle). However, final infarct size, measured on follow-up scintigraphy, was smaller in women, and the percent of myocardium that was salvaged by PCI was greater in women (64 versus 50 percent).",
"   </p>",
"   <p>",
"    Why this might occur is not clear. Contributing factors may include more reactive platelets and therefore a greater response to aggressive antiplatelet therapy and a higher incidence of preinfarction angina, which may limit infarct size by ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies and subset analyses of randomized trials suggest that women with STEMI (like men) have better outcomes with primary PCI than fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/42,50\">",
"     42,50",
"    </a>",
"    ]. In an analysis from the GUSTO-IIb trial of patients treated with primary PCI (without stenting) or fibrinolytic therapy, the adjusted odds ratio for reaching a clinical end point at 30 days (death or nonfatal MI or stroke) was significantly lower with primary PCI compared to fibrinolysis with similar benefit as in men (odds ratio 0.69 versus 0.57 in men) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women, like men, also have better outcomes with primary PCI with stenting compared to angioplasty alone as demonstrated in the CADILLAC trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. Primary stenting in women was associated at one year with a significant reduction in major adverse cardiac events (19.1 versus 28.1 percent) that was entirely due to a reduction in ischemic target vessel revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/49\">",
"     49",
"    </a>",
"    ]. The magnitude of benefit with stenting was similar to that in men (odds ratio for reaching the primary end point with stenting 0.53 versus 0.54 in men) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/52\">",
"     52",
"    </a>",
"    ]. However, since women had a higher rate of events than men, the absolute benefit from stenting was greater. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are somewhat more likely than men to develop cardiogenic shock after STEMI. The magnitude of this effect was illustrated in a report from the GUSTO-I trial of fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/53\">",
"     53",
"    </a>",
"    ]. The hazard ratio for shock in women was significantly increased in women compared to men (hazard ratio 1.22).",
"   </p>",
"   <p>",
"    Among patients who develop cardiogenic shock, female sex is not an independent predictor of outcome. This was illustrated in a report from the SHOCK trial registry of 1190 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/54\">",
"     54",
"    </a>",
"    ]. Although left ventricular failure was the most common etiology for cardiogenic shock in both sex groups, women had a significantly higher incidence of mechanical complications (ventricular septal rupture or acute severe mitral regurgitation) as a cause (19 versus 10.6 percent in men). After adjustment for differences in patient characteristics, women and men had the same in-hospital mortality with medical therapy (79 versus 78 percent) or after revascularization with CABG or PTCA (44 versus 38 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADHERENCE TO GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence-based recommendations have been published by the American Heart Association for the prevention of CHD in women at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/55\">",
"     55",
"    </a>",
"    ]. The goals of secondary prevention in women are not very different from those in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physician compliance with guideline recommendations for evidence-based therapies after an acute myocardial infarction is not optimal. Programs that increase compliance have been associated with improved patient outcomes. The clinical importance of adherence to guidelines is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/44/10953?source=see_link\">",
"     \"Guideline adherence and outcomes in coronary heart disease and heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INVASIVE PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization and coronary revascularization in selected patients are fundamental to the management of coronary disease. Some but not all studies have noted decreased utilization of these procedures in women, suggesting possible sex bias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/10,15,56\">",
"     10,15,56",
"    </a>",
"    ]. However, women often are older and have a greater burden of risk factors than men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Access to procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are less likely than men to undergo cardiac catheterization, but this difference has, in most studies, been appropriate when the difference in risk is taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. This was illustrated in a review of over 143,000 Medicare patients who were admitted for an acute myocardial infarction between 1994 and 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/60\">",
"     60",
"    </a>",
"    ]. Women had significantly lower unadjusted rates of cardiac catheterization (35.7 versus 46.5 percent in men), but this difference largely disappeared with multivariable adjustment (risk standardized rates 40.3 versus 41.9 percent). There was no difference between men and women with strong indications for catheterization; the lower utilization in women was primarily seen in those with equivocal indications, raising the suggestion of overuse of the procedure in men.",
"   </p>",
"   <p>",
"    Women, after adjustment for baseline differences, have a different pattern of access to revascularization compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. This was best illustrated in a report from the Nationwide Independent Sample in the United States that compared 500,000 men to over 300,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/62\">",
"     62",
"    </a>",
"    ]. The unadjusted prevalence ratio (PR) for women undergoing angioplasty, stenting, and coronary bypass was 0.78, 0.76, and 0.74, respectively. However, with adjustment, women were nearly as likely as men to undergo angioplasty or stenting (PR 0.98 and 0.96, respectively); women remained less likely to undergo coronary bypass (PR 0.78). It is unclear whether this represents bias or appropriate medical treatment given the higher mortality of women following CABG (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Bypass surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Data from the CURE trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy in non-ST elevation ACS suggested that outcomes are worse in some women in whom intervention is not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/64\">",
"     64",
"    </a>",
"    ]. Although the rate of angiography, PCI, and CABG was significantly lower in women than men (48 versus 61 percent), there were no significant differences in cardiovascular death, myocardial infarction, or stroke between women and men. However, women were more likely to develop refractory ischemia and to be rehospitalized for chest pain (16.6 versus 13.9 percent).",
"   </p>",
"   <p>",
"    This increase in risk was most prominent in women at high risk as determined from the TIMI risk score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Thus, high risk women should, as in high risk men, be considered for coronary angiography and, if appropriate, revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H8#H8\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'TIMI risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women have a slightly higher risk of death after catheterization than men. In a report from a Canadian registry of over 37,000 patients undergoing catheterization between 1995 and 2000, women had a higher unadjusted mortality rate at one year (5.6 versus 4.6 percent for men) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the excess risk appeared to be concentrated in the early post-catheterization period. After adjusting for women being older and having higher rates of comorbidity, the mortality risk was significantly increased for women compared to men at 30 days, especially for those undergoing CABG or PCI (odds ratios [OR] 2.22 and 1.70 versus 1.40 for those not undergoing revascularization). After 30 days, there was a progressive decrease in the relative risk to equivalence before one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Percutaneous coronary intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women undergoing PCI are older and have a greater burden of risk factors than men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/4,57-59,66-69\">",
"     4,57-59,66-69",
"    </a>",
"    ]. The outcomes in women with PCI have improved over the years. In a study from the NHLBI Registry, the procedural success rate in women was significantly higher in 1997 to 1998 compared to 1985 to 1986 (92 versus 79 percent) and the rate of major complications (death, MI, and emergency CABG) was significantly lower (6.0 versus 11.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/68\">",
"     68",
"    </a>",
"    ]. These improvements occurred despite a higher risk profile in the later registry data and may at least partially be related to the availability of smaller catheters and devices and better access site management. The degree to which they were due to increased use of stents (63 percent) and glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors could not be determined.",
"   </p>",
"   <p>",
"    Data from large national databases suggest that periprocedural mortality after PCI is increased in women compared to men:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report on 118,584 patients from the Healthcare Cost and Utilization Project showed that, after adjusting for other predictors of outcome, mortality remained higher after stenting for women with an MI (4 versus 2 percent for men, adjusted odds ratio 1.47) and without an MI (1.1 versus 0.5 percent, adjusted odds ratio 1.65) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/69\">",
"       69",
"      </a>",
"      ]. Women also had a higher CABG rate after stenting.",
"     </li>",
"     <li>",
"      An analysis from the National Cardiovascular Network Database included over 150.000 patients, approximately one-half of whom received a stent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/67\">",
"       67",
"      </a>",
"      ]. There was a significant increase in in-hospital mortality in women compared to men. This effect was most pronounced in patients under age 50 (adjusted relative risk 1.78), although the absolute mortality rate was very low. This difference persisted after adjustment for body surface area, although such a correction in an earlier report from the same database abolished differences in outcomes between women and men [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adjustment for body surface area has been a presumed surrogate for coronary artery size [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/70\">",
"     70",
"    </a>",
"    ], but women may have smaller coronary arteries independent of body size [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/67\">",
"     67",
"    </a>",
"    ]. Small coronary artery diameter is associated with worse outcomes after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Small coronary arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The short-term and long-term efficacy of stenting in women was examined in a report of 1001 women and 3263 men with symptomatic CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/59\">",
"     59",
"    </a>",
"    ]. The women in this study were older; had a higher incidence of diabetes, hypertension, or hypercholesterolemia; less often had a myocardial infarction; and had better preserved left ventricular function. Women had a higher 30 day rate of death or nonfatal myocardial infarction than men (3.1 versus 1.8 percent for men, adjusted hazard ratio 2.02) but, at one year, the combined cardiac event rate was the same (6 versus 5.8 percent).",
"   </p>",
"   <p>",
"    Drug-eluting stents markedly reduce angiographic and clinical restenosis rates compared to bare metal stents. Data from subset analyses of the randomized TAXUS IV and SIRIUS trials of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stents suggest that the benefit in similar in women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of sex on outcomes was evaluated in a report from the randomized TAXUS IV trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting and bare metal stents; among the 1314 patients in this trial, there were 367 women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/72\">",
"     72",
"    </a>",
"    ]. Women treated with the paclitaxel stent had significant reductions in nine-month restenosis (8.6 versus 29.2 percent) and one-year target lesion revascularization (7.6 versus 14.9 percent).",
"   </p>",
"   <p>",
"    The rate of target lesion revascularization at one year after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stenting was higher in women than men (7.6 versus 3.2 percent). However, as has been demonstrated in other studies cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/4-8,57,58,68\">",
"     4-8,57,58,68",
"    </a>",
"    ], women were older than men and had more comorbidities (diabetes, hypertension, heart failure, renal insufficiency). After adjustment, female sex was not an independent predictor of target lesion revascularization.",
"   </p>",
"   <p>",
"    The benefits of drug-eluting stents on restenosis must be weighed against the possibility of a slightly increased rate of late stent thrombosis, reported in some but not all studies. Late stent thrombosis may lead to death or MI, if dual antiplatelet therapy is prematurely discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon these and other studies, the 2005 statement from the AHA on PCI in women concluded that, although mortality rates after PCI with stenting are similar or higher in women compared to men in a broad range of patient and lesion subsets, any differences are likely due to confounding risk factors, not female sex [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/4\">",
"     4",
"    </a>",
"    ]. Therefore the indication for use of PCI is the same in men and women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similarly high burden of comorbidities exists in women undergoing coronary artery bypass grafting (CABG). Although there has been a significant and similar reduction in in-hospital mortality in women and men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/74\">",
"     74",
"    </a>",
"    ], women still have a greater likelihood of procedural complications (new neurologic event, heart failure, perioperative infarction, and hemorrhage) and death at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/31,75-84\">",
"     31,75-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an analysis from the Society of Thoracic Surgery national database of 416,347 patients undergoing CABG in 1996 and 1997, women had a higher 30 day mortality than men (5.7 versus 3.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/82\">",
"     82",
"    </a>",
"    ]. The increase in mortality compared to men may be most pronounced in patients under age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall increase in short-term mortality in women has been attributed primarily to patient-related factors, including age and coronary risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. As noted above with regard to PCI, another factor that may account for increased in-hospital mortality after CABG is smaller body size with consequently smaller coronary artery size [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/78,85\">",
"     78,85",
"    </a>",
"    ]. During CABG, smaller vessel size may impose more technical difficulties and may be associated with a higher risk of graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the short-term findings, long-term survival after CABG in women is comparable to, or better than, that for men, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis evaluated almost 69,000 patients (including 15,000 women) undergoing isolated CABG in Ontario from 1991 to 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/83\">",
"       83",
"      </a>",
"      ]. Women were older and had more comorbidities than men. Women had modestly higher rates of cardiac readmission in the first year after surgery and thereafter, due primarily to unstable angina and heart failure. After propensity matching, women had a lower mortality rate after discharge (hazard ratio 0.90, 95% CI 0.83-0.98) and a similar rate of repeat revascularization.",
"     </li>",
"     <li>",
"      In the BARI trial of revascularization (comparing PTCA and CABG) in 1829 markedly symptomatic patients with two or three vessel coronary disease, 27 percent were women [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/86\">",
"       86",
"      </a>",
"      ]. Crude mortality rates at 5.4 years were similar for women and men (12.8 and 12.0 percent). However, women were older and had more heart failure, hypertension, and diabetes; with adjustment for these and other baseline differences, the relative risk of death for women was 0.6 (95% CI 0.4-0.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=see_link\">",
"     \"Patient information: Coronary heart disease in women (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3136765\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are significant differences between men and women in the epidemiology, diagnosis, and prognosis of CHD that should be taken into account in the care of women with known or suspected disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=see_link\">",
"       \"Clinical features and diagnosis of coronary heart disease in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28217?source=see_link\">",
"       \"Coronary heart disease and myocardial infarction in young men and women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hormone replacement therapy is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for cardiac protection in women with CHD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For primary prevention satins are effective, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is of benefit in preventing stroke in all women and MI in those 65 years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of beta blockers after myocardial infarction (MI) is well demonstrated in women. Although efficacy in women has not been specifically studied, the criteria for ACE inhibitor therapy should be the same as in men. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with a non-ST elevation MI should be managed in a manner similar to men [",
"      <a class=\"abstract\" href=\"UTD.htm?10/63/11258/abstract/9\">",
"       9",
"      </a>",
"      ]. Women, like men, with high risk features benefit from an early invasive strategy within the first 48 hours. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Non-ST elevation acute coronary syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with ST-elevation MI should generally be treated the similarly to men. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'ST elevation MI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/1\">",
"      Eaker ED, Chesebro JH, Sacks FM, et al. Cardiovascular disease in women. Circulation 1993; 88:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/2\">",
"      Mosca L, Manson JE, Sutherland SE, et al. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1997; 96:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/3\">",
"      Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001; 286:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/4\">",
"      Lansky AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation 2005; 111:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/5\">",
"      Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005; 45:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/6\">",
"      White HD, Barbash GI, Modan M, et al. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. Circulation 1993; 88:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/7\">",
"      Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999; 341:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/8\">",
"      Mehilli J, Ndrepepa G, Kastrati A, et al. Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. J Am Coll Cardiol 2005; 45:828.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/10\">",
"      Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol 1999; 84:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/11\">",
"      LaCroix AZ, Guralnik JM, Curb JD, et al. Chest pain and coronary heart disease mortality among older men and women in three communities. Circulation 1990; 81:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/12\">",
"      Gan SC, Beaver SK, Houck PM, et al. Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med 2000; 343:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/13\">",
"      Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med 1994; 120:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/14\">",
"      Barakat K, Wilkinson P, Suliman A, et al. Acute myocardial infarction in women: contribution of treatment variables to adverse outcome. Am Heart J 2000; 140:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/15\">",
"      Daly C, Clemens F, Lopez Sendon JL, et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006; 113:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/16\">",
"      Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/17\">",
"      Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/18\">",
"      Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/19\">",
"      de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/20\">",
"      Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/21\">",
"      Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006; 295:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/22\">",
"      Clarke KW, Gray D, Keating NA, Hampton JR. Do women with acute myocardial infarction receive the same treatment as men? BMJ 1994; 309:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/23\">",
"      Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/24\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/25\">",
"      Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/26\">",
"      Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/27\">",
"      Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/28\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/29\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/30\">",
"      Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/31\">",
"      Lagerqvist B, S&auml;fstr&ouml;m K, St&aring;hle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol 2001; 38:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/32\">",
"      Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/33\">",
"      Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002; 288:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/34\">",
"      Mueller C, Neumann FJ, Roskamm H, et al. Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1,450 consecutive patients. J Am Coll Cardiol 2002; 40:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/35\">",
"      Hochman JS, Tamis-Holland JE. Acute coronary syndromes: does sex matter? JAMA 2002; 288:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/36\">",
"      Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/37\">",
"      Maynard C, Litwin PE, Martin JS, Weaver WD. Gender differences in the treatment and outcome of acute myocardial infarction. Results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med 1992; 152:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/38\">",
"      Heer T, Schiele R, Schneider S, et al. Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol 2002; 89:511.",
"     </a>",
"    </li>",
"    <li>",
"     Collins L, Douglas PS. Acute myocardial infarction in women. In: Acute Myocardial Infarction, 2nd ed, Gersh B, Rahimtoola S (Eds), Chapman &amp; Hall, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/40\">",
"      Gottlieb S, Harpaz D, Shotan A, et al. Sex differences in management and outcome after acute myocardial infarction in the 1990s: A prospective observational community-based study. Israeli Thrombolytic Survey Group. Circulation 2000; 102:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/41\">",
"      Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999; 341:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/42\">",
"      Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 1995; 75:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/43\">",
"      Woodfield SL, Lundergan CF, Reiner JS, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol 1997; 29:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/44\">",
"      Karnash SL, Granger CB, White HD, et al. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J Am Coll Cardiol 1995; 26:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/45\">",
"      Hannan EL, Racz MJ, Arani DT, et al. Short- and long-term mortality for patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2000; 36:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/46\">",
"      Vakili BA, Kaplan RC, Brown DL. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation 2001; 104:3034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/47\">",
"      Azar RR, Waters DD, McKay RG, et al. Short- and medium-term outcome differences in women and men after primary percutaneous transluminal mechanical revascularization for acute myocardial infarction. Am J Cardiol 2000; 85:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/48\">",
"      Antoniucci D, Valenti R, Moschi G, et al. Sex-based differences in clinical and angiographic outcomes after primary angioplasty or stenting for acute myocardial infarction. Am J Cardiol 2001; 87:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/49\">",
"      Lansky AJ, Pietras C, Costa RA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2005; 111:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/50\">",
"      Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. Am Heart J 2004; 147:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/51\">",
"      Mehilli J, Kastrati A, Dirschinger J, et al. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. JAMA 2002; 287:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/52\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/53\">",
"      Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000; 35:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/54\">",
"      Wong SC, Sleeper LA, Monrad ES, et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. J Am Coll Cardiol 2001; 38:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/55\">",
"      Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007; 115:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/56\">",
"      Lehmann JB, Wehner PS, Lehmann CU, Savory LM. Gender bias in the evaluation of chest pain in the emergency department. Am J Cardiol 1996; 77:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/57\">",
"      Kelsey SF, James M, Holubkov AL, et al. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993; 87:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/58\">",
"      Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men. J Am Coll Cardiol 1994; 24:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/59\">",
"      Mehilli J, Kastrati A, Dirschinger J, et al. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA 2000; 284:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/60\">",
"      Rathore SS, Wang Y, Radford MJ, et al. Sex differences in cardiac catheterization after acute myocardial infarction: the role of procedure appropriateness. Ann Intern Med 2002; 137:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/61\">",
"      Miller TD, Roger VL, Hodge DO, et al. Gender differences and temporal trends in clinical characteristics, stress test results and use of invasive procedures in patients undergoing evaluation for coronary artery disease. J Am Coll Cardiol 2001; 38:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/62\">",
"      Bertoni AG, Bonds DE, Lovato J, et al. Sex disparities in procedure use for acute myocardial infarction in the United States, 1995 to 2001. Am Heart J 2004; 147:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/63\">",
"      Ghali WA, Faris PD, Galbraith PD, et al. Sex differences in access to coronary revascularization after cardiac catheterization: importance of detailed clinical data. Ann Intern Med 2002; 136:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/64\">",
"      Anand SS, Xie CC, Mehta S, et al. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. J Am Coll Cardiol 2005; 46:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/65\">",
"      King KM, Ghali WA, Faris PD, et al. Sex differences in outcomes after cardiac catheterization: effect modification by treatment strategy and time. JAMA 2004; 291:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/66\">",
"      Peterson ED, Lansky AJ, Kramer J, et al. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am J Cardiol 2001; 88:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/67\">",
"      Abramson JL, Veledar E, Weintraub WS, Vaccarino V. Association between gender and in-hospital mortality after percutaneous coronary intervention according to age. Am J Cardiol 2003; 91:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/68\">",
"      Jacobs AK, Johnston JM, Haviland A, et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol 2002; 39:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/69\">",
"      Watanabe CT, Maynard C, Ritchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol 2001; 88:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/70\">",
"      Jacobs AK. Coronary revascularization in women in 2003: sex revisited. Circulation 2003; 107:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/71\">",
"      Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999; 34:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/72\">",
"      Lansky AJ, Costa RA, Mooney M, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 2005; 45:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/73\">",
"      Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/74\">",
"      O'Rourke DJ, Malenka DJ, Olmstead EM, et al. Improved in-hospital mortality in women undergoing coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 2001; 71:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/75\">",
"      Fisher LD, Kennedy JW, Davis KB, et al. Association of sex, physical size, and operative mortality after coronary artery bypass in the Coronary Artery Surgery Study (CASS). J Thorac Cardiovasc Surg 1982; 84:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/76\">",
"      Loop FD, Golding LR, MacMillan JP, et al. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol 1983; 1:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/77\">",
"      Weintraub WS, Wenger NK, Jones EL, et al. Changing clinical characteristics of coronary surgery patients. Differences between men and women. Circulation 1993; 88:II79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/78\">",
"      O'Connor GT, Morton JR, Diehl MJ, et al. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. The Northern New England Cardiovascular Disease Study Group. Circulation 1993; 88:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/79\">",
"      Brandrup-Wognsen G, Berggren H, Hartford M, et al. Female sex is associated with increased mortality and morbidity early, but not late, after coronary artery bypass grafting. Eur Heart J 1996; 17:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/80\">",
"      Edwards FH, Carey JS, Grover FL, et al. Impact of gender on coronary bypass operative mortality. Ann Thorac Surg 1998; 66:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/81\">",
"      Hartz RS, Rao AV, Plomondon ME, et al. Effects of race, with or without gender, on operative mortality after coronary artery bypass grafting: a study using The Society of Thoracic Surgeons National Database. Ann Thorac Surg 2001; 71:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/82\">",
"      Hogue CW Jr, Barzilai B, Pieper KS, et al. Sex differences in neurological outcomes and mortality after cardiac surgery: a society of thoracic surgery national database report. Circulation 2001; 103:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/83\">",
"      Guru V, Fremes SE, Austin PC, et al. Gender differences in outcomes after hospital discharge from coronary artery bypass grafting. Circulation 2006; 113:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/84\">",
"      Vaccarino V, Abramson JL, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation 2002; 105:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/85\">",
"      O'Connor NJ, Morton JR, Birkmeyer JD, et al. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 1996; 93:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/63/11258/abstract/86\">",
"      Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). Circulation 1998; 98:1279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1520 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11258=[""].join("\n");
var outline_f10_63_11258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3136765\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NON-ST ELEVATION ACUTE CORONARY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Early invasive strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ST ELEVATION MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coronary reperfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADHERENCE TO GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INVASIVE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Access to procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3136765\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1520\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1520|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10062\" title=\"figure 1\">",
"      Coronary death vs sex race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/13/28894\" title=\"figure 2A\">",
"      In hospital mortality by gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/49/14109\" title=\"figure 2B\">",
"      Survival MI by gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/34/23085\" title=\"figure 3\">",
"      HRT and CHD HERS II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/54/11118\" title=\"figure 4\">",
"      Pravastatin and MACE rates in men versus women CARE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/28/6592\" title=\"figure 5\">",
"      Statin benefits by tertile HPS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41113?source=related_link\">",
"      Clinical features and diagnosis of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/44/10953?source=related_link\">",
"      Guideline adherence and outcomes in coronary heart disease and heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=related_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=related_link\">",
"      Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_63_11259="Sources of infection in febrile young infants";
var content_f10_63_11259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common sources of infection in febrile infants under 90 days of age (N = 105)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of serious bacterial infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence&nbsp;&nbsp;(%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteremia",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft tissue infection",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Percentages do not add up to 100 percent because some individuals had more than one type of infection.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Byington, CL, Enriquez, FR, Hoff, C, et al. Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections. Pediatrics 2004; 113:1662.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11259=[""].join("\n");
var outline_f10_63_11259=null;
var title_f10_63_11260="Isopropyl alcohol metabolism";
var content_f10_63_11260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Isopropyl alcohol metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 204px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11260=[""].join("\n");
var outline_f10_63_11260=null;
var title_f10_63_11261="ABCD rule of dermoscopy";
var content_f10_63_11261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ABCD rule of dermoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score range",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\">",
"        Multiply points by factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        FDS* range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        0-2",
"       </td>",
"       <td rowspan=\"3\">",
"        <strong>",
"         A",
"        </strong>",
"        symmetry",
"       </td>",
"       <td>",
"        No asymmetry",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td rowspan=\"3\">",
"        x 1.3",
"       </td>",
"       <td rowspan=\"3\">",
"        0-2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mono-axial asymmetry",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bi-axial asymmetry",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        0-8",
"       </td>",
"       <td rowspan=\"9\">",
"        <strong>",
"         B",
"        </strong>",
"        order",
"       </td>",
"       <td>",
"        No sharp border",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td rowspan=\"9\">",
"        x 0.1",
"       </td>",
"       <td rowspan=\"9\">",
"        0-0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One segment with sharp border",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two segments with sharp border",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Three segments with sharp border",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four segments with sharp border",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Five segments with sharp border",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Six segments with sharp border",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seven segments with sharp border",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eight segments with sharp border",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        1-6",
"       </td>",
"       <td rowspan=\"6\">",
"        <strong>",
"         C",
"        </strong>",
"        olor",
"       </td>",
"       <td>",
"        White",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td rowspan=\"6\">",
"        x 0.5",
"       </td>",
"       <td rowspan=\"6\">",
"        0.5-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Light brown",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dark brown",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blue-gray",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Black",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        1-5",
"       </td>",
"       <td rowspan=\"5\">",
"        <strong>",
"         D",
"        </strong>",
"        ermoscopic structure",
"       </td>",
"       <td>",
"        Network",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td rowspan=\"5\">",
"        x 0.5",
"       </td>",
"       <td rowspan=\"5\">",
"        0.5-2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aggregated globules",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dots",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Structureless areas",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Branched streaks",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" colspan=\"5\">",
"        <strong>",
"         FDS range:",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1-8.9",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * FDS: final dermoscopy score. &lt;4.75 = benign; 4.75 to 5.45 = suspicious; &gt;5.45 = malignant.",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Nachbar F, Stolz W, Merkle T, et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. J Am Acad Dermatol 1994; 30:551. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11261=[""].join("\n");
var outline_f10_63_11261=null;
var title_f10_63_11262="Treatment of Kawasaki";
var content_f10_63_11262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for the treatment of Kawasaki disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 273px; height: 461px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11262=[""].join("\n");
var outline_f10_63_11262=null;
var title_f10_63_11263="Landmarks diagnosis Barretts";
var content_f10_63_11263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomic landmarks for the diagnosis of Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The squamocolumnar junction (SCJ or Z-line) is the visible line formed by the juxtaposition of squamous and columnar epithelia. The gastroesophageal junction (GEJ) is the imaginary line at which the esophagus ends and the stomach begins. The GEJ corresponds to the most proximal extent of the gastric folds. When the SCJ is located proximal to the GEJ, there is a columnar-lined segment of esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117:218.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_63_11263=[""].join("\n");
var outline_f10_63_11263=null;
